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Abstract
Recent research indicates that protein kinase C (PKC) plays an important role in smooth
muscle contraction. Because PKC activation and specificity of substrate phosphorylation
is believed to be associated with the relocalization of the enzyme to specific cell sites, we
first investigated the subcellular translocation of PKCα in A7r5 smooth muscle cells by
confocal microscopy through use of standard immunohistologic staining and PKCα enhanced green fluorescent protein (PKCα -EGFP) fusion protein expression. PKCα was
diffusely distributed throughout the cytosol in the unstimulated A7r5 cell. Upon
stimulation with phorbol 12, 13 dibutyrate (PDBu), PKCα was translocated primarily to
either the perinuclear region of the cell or to subplasmalemmal sites depending on the
concentration of the stimulating agent. Specifically, PKCα was translocated to the
perinuclear area in response to high PDBu concentrations (10-5 M to10-6 M) and relocated
to the plasma membrane at lower PDBu concentrations (10-7 M to10-8 M). Translocation
of PKCα to the perinucleus but not the plasmalemma was blocked by the use of
colchicine to disrupt cell microtubules. By comparison, cytochalasin B disruption of
actin microfilaments had no significant effect on PKCα translocation to either the
plasmalemma or the perinucleus. The results indicate that the target site of PKCα
translocation may vary with activating stimulus strength in A7r5 cells and that the
translocation of the isoform to the perinuclear region of the cell is dependent on an intact
microtubular cytoskeleton. This suggests that multiple pathways are available for the
redistribution of PKCα that may employ different mechanisms to regulate the movement
and/or docking of the isoform at specific target sites.
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We next compared the spatial and temporal pattern of PKCα translocation in response to
different stimulating agents in live A7r5 smooth muscle cell preparations utilizing cells
transfected with PKCα-EGFP. PDBu (10-8 M) induced a slow but robust and irreversible
relocation of the PKCα -EGFP fusion protein from the cytosol to the plasmalemma. By
comparison, thapsigargin (10-5 M) and A23187 (2 X 10-5 M) induced a rapidly transient
translocation to the cell membrane, which was completed within 4 minutes. In contrast to
these agents, angiotensin II (Ang II, 10-6 M) caused only partial relocalization of
cytosolic PKCα-EGFP to brightly fluorescing patches at the cell periphery. Moreover, the
translocation of the kinase to peripheral patches was completed within seconds and the
fusion protein returned to the cytosol within 2 minutes. The PKC inhibitor staurosporine
blocked cellular contraction to PDBu but not to A23187 and had no effect on PKCαEGFP translocation. By comparison, the calcium chelators EDTA and BAPTA-AM
blocked the contraction to A23187, attenuated the contraction to PDBu, and abolished the
translocation of PKCα-EGFP by both agents. The results show that A7r5 cells retain the
ability to respond to several types of contractile agents and the spatial and temporal
characteristics of individual PKC isoform translocation may differ markedly, depending
on the stimulating agent.

The mechanism of vascular smooth muscle contraction is not well understood. Early
research from our laboratory has suggested that stimulation of contraction in A7r5
smooth muscle cells with phorbol ester (PDBu) results in remodeling of the actin
component of the cytoskeleton. Because the elevation of intracellular calcium ([Ca2+]i) is
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thought to be the initiating event of smooth muscle cell contraction to the majority of
physiological agonists, we examined the effect of increasing [Ca2+]i by A23187 and
thapsigargin on α- and β-actin remodeling. Contraction of A7r5 cells induced by A23187
and thapsigargin was earlier in onset and more quickly completed than PDBu-induced
contractions. During the interval of contraction induced by A23187 and thapsigargin, βactin cables shortened without evidence of disassembly. In marked contrast, elevation of
intracellular calcium resulted in the partial or complete dissolution of α-actin cables and
blocked further α-actin remodeling in response to PDBu. The α-actin associated crosslinking protein α-actinin showed a similar pattern of dissolution in response to high
calcium, while the distribution of anchor protein talin was unchanged. Finally, incubation
of the cells in the calcium-free medium prevented α-actin dissolution by
A23187/thapsigargin and blocked PDBu-mediated α-actin remodeling. The results
suggest that extracellular calcium is necessary for α-actin remodeling and that the
elevation of [Ca2+]i beyond a threshold level initiates disassembly of α-actin cable
structure in a highly selective fashion. We have further observed that of six kinase
inhibitors investigated only ML-7, a myosin light chain kinase (MLCK) inhibitor,
blocked the dissolution of α-actin cables induced by increased [Ca2+]i. This finding may
be suggesting a novel role of MLCK in destabilizing α-actin structure in the [Ca2+]i
activated smooth muscle cell.
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I Literature Review

Smooth Muscle Contraction: Smooth muscle is found to be mainly present in the
cylindrical or hollow organs of six different systems: gastrointestinal, ocular,
reproductive, respiratory, urinary and vascular. Therefore, the functions of the organs
containing smooth muscle are storage and transport, and smooth muscle is often
considered a tissue of conductance and capacitance. This does not indicate that smooth
muscle is an inert tissue, serving only as a conduit for various fluids. In the
cardiovascular system, the active nature of smooth muscle is best observed. After
contraction of the heart and propulsion of blood through the vasculature, it is the resting
tone of the vessels that is the major determinant of the fluid dynamics of the system. The
functions carried out by the smooth muscle in all systems are based on its excitable
nature and ability to contract.

Major unanswered questions concerning smooth muscle contractile properties include
concerned with the mechanism by which it develops force and the complete signal
pathway. Most of the information available on how cells develop force was derived from
the study of striated muscle that is characterized by an ordered arrangement of regularly
spaced sarcomeres that move closer together upon contractile stimulation. Early research
revealed the sarcomeres in striated muscle to be mainly comprised of actin and myosin.
The basic principles of sliding filament theory, which evolved from structural and
biochemical studies of the sarcomere, indicate that the initial increases in intracellular
calcium after muscle stimulation results in calcium binding to troponin. This binding
causes a shift of tropomyosin from its resting position in the grooves within the actin
helices, thereby removing inhibition of interaction between actin and myosin. The
interaction of actin and myosin activates the ATPase in the myosin head, and stable
crossbridges between the sarcomeric actin and myosin filaments are formed. Following
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this, the hydrolysis of ATP and the conformational change of myosin induced by
hydrolysis of ATP provide the force necessary to pull the actin and myosin past each
other. These biochemical events combined with the opposing interdigitation of the actin
and myosin filaments produce a shortening of each individual contractile unit sarcomere
and force development.

Figure 1.
Activation scheme of smooth muscle contraction. G, heterotrimeric GTP-binding protein;
R, receptor; L, ligand; IP3, inositol 1,4,5-trisphosphate; SR, sarcoplasmic reticulum;
CaM, calmodulin; MLCK, myosin light-chain kinase; MLCP, myosin light-chain
phosphatase.
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Smooth muscle has no morphologically recognizable sarcomere. Despite the gross
morphological differences between striated and smooth muscle, most of the initial work
concerning the biochemistry and biophysics of smooth muscle contraction was analyzed
and presented within the existing parameters that had been determined for striated muscle
contraction. The most widely accepted mechanism is that the contraction of smooth
muscle is induced by the elevation of [Ca2+]i which, in turn, activates myosin light chain
kinase to initiate the actin/myosin interaction and contraction (Fig. 1). A number of
extracellular signals, including neural, humoral, ionic, and mechanical forces, result in an
increase in intracellular calcium from 120-270 nM to 500-700 nM and the high
intracellular calcium induces binding of free calcium to calmodulin (CaM) to form Ca2+4CaM complex. Formation of this complex induces a conformational change in CaM with
exposure of a site of interaction with the target protein myosin light chain kinase
(MLCK), resulting in formation of the complex Ca2+4-CaM-MLCK, which is the active
from of kinase. The active MLCK phosphorylates the serine 19 in each of the two 20-kD
myosin light chains (LC20), triggering the cross-bridge cycling of actin-myosin and
development of force with the hydrolysis of ATP. After an excitation, relaxation and
calcium homeostasis are achieved by calcium reuptake into intracellular stores and the
extrusion into extracellular space.

Intracellular Calcium The main site of calcium storage inside smooth muscle cell is
the sarcoplasmic reticulum (SR), and this organelle plays a major role in maintaining low
intracellular [Ca2+]. Although the volume of SR appears to vary between smooth muscles,
the SR forms an extensive intracellular network, which is capable of calcium uptake,
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storage, and specialized release. SR volume is estimated to be 1.5-7.5% of smooth
muscle cell volume. SR is typically more abundant in tonic (for example, aorta) than
phasic (such as portal vein) smooth muscle. Most of the surface of SR in smooth muscles
is closely associated with the plasma membrane (Devine et al., 1972), so release of
calcium can greatly affect the concentration of calcium near the inner surface of the
plasma membrane as well as the calcium concentration in the cytosol. The SR is
surrounded by a membrane that is not freely permeable to calcium. Active calciumATPases, which are known as SERCA pumps, exist in the SR membrane and generate
and maintain about a 10,000-fold calcium gradient between the SR lumen and the
cytoplasm. Three genes encode SERCA pumps, and two subgroups of SERCA2
(SERCA2a and SERCA2b) have been identified. SERCA pumps utilize the energy from
ATP hydrolysis to move calcium from the cytoplasm to the lumen of the SR. After
calcium is pumped into the SR, it is buffered by calcium binding proteins, such as
calreticulin and calsequestrin. Studies of the function of SERCA pumps have been
strongly aided by specific SERCA pump inhibitors, such as thapsigargin. When SERCA
pumps are inhibited by thapsigargin, a major source of calcium regulation is lost and
calcium leaks into the cytoplasm. Because cells are unable to maintain typically low
cytoplasmic concentrations, intracellular calcium concentrations increase. This effect
will induce further increase of intracellular calcium concentration or extend periods of
contraction. Evidence from a variety of cell types suggests that mitochondria also play an
important role in calcium homeostasis
Stimulation of smooth muscle by agonists that bind to certain types of G-protein-coupled
membrane receptors results in the activation of phospholipase C and production of IP3 by
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hydrolysis of phosphatidylinositol. IP3 induces calcium release from the SR by
activating one type of calcium release channel, which is called the IP3 receptor. Three
genes encode IP3 receptors and each channel is made up of four subunits of about 300
kDa that form a homotetrameric or heterotetrameric structures. An increase of calcium
concentration from basal level to 300nM will further increase the potency of IP3 in
activating calcium channels, and cause more calcium release. However, higher calcium
concentrations reduce the effectiveness of IP3 and result in negative feedback for release
of calcium. Another major source of calcium channel-associated SR release of calcium
involves the ryanodine receptor. Cytoplasmic calcium can activate ryanodine receptors,
and, as a result, this release pathway is referred as the calcium –induced calcium release
channel. It is possible that the release of calcium from IP3 receptors stimulates the
release of calcium from ryanodine receptors.

The Cytoskeleton The smooth muscle cytoskeleton is composed of three principal
types of protein filaments (actin filaments, intermediate filaments and microtubules),
which form protein filament networks extending throughout the cytoplasm. The
cytoskeleton is a dynamic structure that is continually reorganized as cells move, change
shape, or contract.

Actin The major smooth muscle cytoskeleton protein, actin, is involved in vesicle
trafficking, cell division, cell motility and muscle contraction (Barkalow and Hartwig,
1995). Actin exists as monomeric, G-actin, or as filamentous, F-actin. The G-actin
polymerizes to form F-actin filaments which are thin, flexible fibers approximately 7 nm
is diameter and up to several mm in length. The formation of F-actin from G-actin is a
two-step process. In vitro, the first step, the rate-limiting step for filament assembly, is
nucleation: formation of actin dimers and trimers (Cooper et al., 1983; Frieden, 1983;
Tobacman et al., 1983). The nucleation of actin filaments in vivo is poorly understood,
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but research indicates that the Arp2/3 complex plays a possible key role in nucleation.
After nucleation, rapid elongation of actin filaments occurs (Korn, 1982). Since all actin
monomers are oriented in the same direction, actin filaments have a distinct polarity with
the two ends (plus and minus ends) being distinguishable from one another. These two
ends of an actin filament grow at different rates. The G-actin is added to the plus end five
to ten times faster than to the minus end. Therefore the plus end is kinetically favored for
assembly. This polarity of actin filaments is important in establishing a unique direction
of myosin movement relative to actin.

There is a very high degree of conservation of actin sequence within cell types with a 95
percent amino acid sequence homology (Pollard and Cooper, 1986). In vertebrate
animals, six distinct actin isoforms have been identified: α-skeletal, α-cardiac, αvascular, γ-enteric, γ-cytoplasmic and β-cytoplasmic. Each is encoded by a distinct gene
(Vandekerckhove and Weber, 1978; Reddy et al., 1990). The isoforms found in smooth
muscle are α-actin, β-actin, and γ-actin (Herman, 1993), they only differ in their Ntermini (Vandekerckhove and Weber, 1981). These isoforms are categorized into muscle
actin (α-actin and γ-actin) and cytoplasmic actin (β and γ-actin). Of the cytoplasmic
actins, β-actin is the most predominant, comprising up to thirty percent of the total
cellular actin complement (North et al., 1994a). There appears to be a cellular
compartmentalization of these isoforms. Antibodies directed against the α and γ-actin but
not β-actin colocalized with the myosin containing contractile region (North et al.,
1994b). It was suggested that this compartmentalization was a reflection of function by
Small (1986) who hypothesized that contraction was generated through the actin:myosin
containing portion of the cell.

The idea that there is a relationship between contraction and cytoskeleton remodeling was
first proposed in the early 1990s. Based on studies of single smooth muscle cells, it was
6

shown that the length-tension relationship changed depending on the initial length at
which the cells were activated. It was first suggested by Harris and Warshaw (1991) that
there was a disassociation of cell length and contractile element length. Subsequent
studies showed that velocity of shortening decreased as the tissue was activated at
increasing lengths, leading Gunst and coworkers (1993) to conclude that their results
were consistent with an the hypothesis of Harris and Warshaw (1990), who proposed that
the decrease in velocity of shortening in single cell contractions is due to an internal load
that increases as the cell shortens. Gunst suggested that the internal load could represent
resistance to shortening resulting from the compression of the cytoskeleton. It was
further speculated by Gunst et al. (1993) that the inverse relationship between tissue
length at activation and velocity of shortening could reflect the reorganization of the
cytoskeleton in response to activation at different muscle lengths. They suggested that
reorganization would serve to maximize contractile function at each tissue length and
could involve the activation-induced attachment of the contractile component of the
cytoskeleton to stabilizing cell structures. This research group proposed later that the
depression of force seen during the oscillation in length of canine tracheal smooth muscle
was due to the resetting of contractile element length as a result of muscle stretch (Shen
et al., 1997).

Our laboratory first demonstrated that inhibition of actin polymerization by cytochalasin
caused a selective blockade of the slow tension increase in rat aortic smooth muscle
(Wright and Hurn, 1994). Rather than a fixed resetting of the cytoskeleton to optimize
length-tension at activation, Wright and Hurn (1994) suggested that slow tension
development by smooth muscle required a capability for dynamic remodeling of a portion
of the actin cytoskeleton during the interval of contraction. Their conclusion has been
supported by recent studies of Mehta and Gunst (1999), who showed that inhibition of
actin polymerization by latrunculin-A depressed force development without affecting
7

myosin light chain phosphorylation, further suggesting that actin polymerization
contributes directly to force development. Wright and Battistella-Patterson (1998) have
shown that inhibition of actin polymerization blocks calcium-dependent stress relaxation
in vascular smooth muscle, suggesting that remodeling of the actin cytoskeleton may also
serve to decrease cellular tension following abrupt stretch. Taken together, it is clear that
effects of inhibition of actin polymerization on the contractile and stress relaxant
properties of smooth muscle cannot be attributed to a simple loss in cytoskeletal
structure. However, Wright’s conclusions are consistent with an inhibition of dynamic
actin cytoskeletal remodeling which could serve to continuously modulate the optimal
positioning of actin and myosin filaments during the interval of force development and
cell constriction (Battistella-Patterson et al., 1997; Fultz et al., 2000). Nevertheless, the
cytochalasin-based studies have been the subject of controversy.

Cytochalasins are a class of fungal metabolites first derived from cultures of
Helminthosporium dematioideum and Metarrhizium anisopliae in the late 1960’s (Carter,
1967). Cytochalasins were shown to cause microfilaments to lose their filamentous nature
(Schroeder, 1970; Wessells, 1971). These microfilaments were later shown to be the
actin filaments (Spudich, 1972; Spudich and Lin, 1972). Cytochalasin B inhibits actin
polymerization by binding to the plus end of actin filaments, thereby inhibiting the
addition of actin monomers to existing filaments (Cooper, 1987). It was unknown
whether the inhibitory effect of cytochalasins on smooth muscle contraction was through
the effect of cytochalasin on the polymerizing actin cytoskeleton or due to an unknown or
nonspecific effect of the drug (Wessells, 1971). For example, there is some evidence
indicating the effect of cytochalasin on smooth muscle contraction could be through the
blockade of calcium influx (Dresel and Ogbaghebriel, 1988), the blockade of glucose
uptake (Dresel and Knickle, 1987), the inhibition of myosin light chain phosphorylation
or the inhibition of myosin ATPase activity. However, Obara and Yabu (1994) have
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shown that treatment of smooth muscle tissues with cytochalasin at a concentration that
induced a maximal inhibition of the contraction, had no effect on cell calcium current,
myosin light chain phosphorylation or myosin ATPase activity in response to high
potassium contraction. It was reported by Tseng et al (1997) that there was an absence of
an effect of cytochalasin on glucose transport at the concentration necessary to produce
maximal inhibition. Because the stable actin structure of striated muscle is not affected by
cytochalasin, it may suggest that the fast phase of smooth muscle contraction, which is
also unaffected by cytochalasin (Wright and Hurn, 1994), is produced by a mechanism
comparable to sliding filament-based systems. At this time, however, the role of dynamic
actin cytoskeleton remodeling as a potential factor in the development of slow phase
smooth muscle contraction has yet to be clearly elucidated.

Recent studies of the contractile response of A7r5 smooth cells to phorbol ester, which
activates slow tension development, indicate significant actin remodeling, with the
remodeling of α and β-actin being distinctly different (Fultz et al., 2000). Both isoforms
were incorporated into stress cables in the unstimulated cell. During the interval of
contraction, β-actin cables were stable and observed to shorten without evidence of
disassembly. In contrast, α-actin cables were clearly observed to disassemble and reform
into a system of peripheral column-like structures with associated clusters of randomly
oriented fibers. Although subject to controversy, there is evidence that the phorbol esterinduced contraction of smooth muscle may occur in the absence of an elevation in [Ca2+]i
(Nakajima et al., 1993) or a concomitant increase in myosin light chain phosphorylation
(Singer and Baker, 1987).

Intermediate Filaments Intermediate filaments have a diameter of 10 nm. Their main
function is to provide mechanical strength to cells. Intermediate filaments have been
proposed to play an indirect role in the contractile process through the positioning of
9

dense bodies in the cell. It has been suggested that dense bodies constitute cellular
anchorage points in smooth muscle that are analogues to the Z-line in striated muscles
(Bond and Somlyo, 1982; Kargacin et al., 1989). Actin filaments anchored at dense
bodies have been presumed to transmit tension to the cell surface via connections to
subplasmalemmal dense plaques (Pease and Molinari, 1960). These dense bodies have
been shown to contain α-actinin (Fay et al., 1983), filamin (Small et al., 1986), talin
(Volberg et al, 1986), vinculin (Geiger et al., 1985; Volberg et al., 1986), plectin (Wiche
et al., 1983) and actin.

Microtubules There is no evidence to indicate the involvement of microtubules in
smooth muscle contraction. Microtubules have been shown to be involved in a variety of
cellular functions including: formation of the mitotic spindle, axonal and dendritic
extension in neurons, maintenance of intracellular organization and shape, transport of
compounds and organelles (Avila, 1991), and cell motility (Bershadsky and Vasiliev,
1993). Microtubules are rigid hollow rods approximately 25 nm in diameter and are
formed by the reversible polymerization of tubulin. Like actin filaments, the microtubules
have a distinct polarity with a greater addition rate of tubulin at the plus end than at the
minus end. There are three types of tubulin that comprise the microtubule, α,β and γ. The
α and β-tubulin form dimers and these dimers can attach to the growing microtubule. γTubulin is found at the centrosome, the microtubule organizing center (MTOC), and site
for polymerization (Oakley and Oakley, 1989; Zheng et al., 1991). This degree of
organization ensures that microtubular polymerization can only occur in a direction away
from the MTOC (Brinkley, 1985). The transport function of microtubules is
accomplished by microtubule-associated motor proteins: kinesin and dynein. Both of
these proteins consist of a heavy chain and of a light chain. The heavy chain binds to the
microtubule and generates force through hydrolysis of ATP, while the light chain is
responsible for binding a specific “cargo”. A major difference between the two motor
10

proteins is based on the polarity of transport along the microtubules: kinesin is a plus-end
oriented motor protein, moving away from the MTOC, and dynein is a minus enddirected motor, moving toward the MTOC. This type of system allows for specific and
directed bi-directional transport of compounds and organelles. Colchicine, which causes
depolymerization of the microtubules into free tubulin, is known to cause a disruption of
the cellular morphology, producing “fractures” within the cytoplasm (Godman, 1955).

Kinases Thought to be Involved in Smooth Muscle Contraction Although the exact
nature of the signaling pathways that regulate smooth muscle contraction are not certain,
recent use of pharmacological and molecular approaches indicates that several specific
families of kinase are involved in determining the contractile response to different
agonists. Those that have been repeatedly demonstrated to be important are discussed
below.

Myosin Light Chain Kinase (MLCK) MLCK is a calcium/calmodulin-dependent
protein kinase that phosphorylates a serine residue in the N-terminus of the regulatory
light chain (RLC) of myosin II (Stull et al., 1986; Gallagher et al., 1997). The RLC of
myosin II is its only identified physiological substrate, so the enzyme is recognized as a
dedicated kinase. Phosphorylation of the RLC of myosin II by calcium/calmodulindependent MLCK plays diverse roles in cellular functions including, potentiated skeletal
and cardiac muscle contraction (Sweeney et al., 1993), initiation of smooth muscle
contraction (Kamm & Stull, 1985; Hartshorne, 1987; Somlyo & Somlyo, 1994; Gallagher
et al., 1997), platelet aggregation and contraction, endothelial cell retraction, fibroblast
contraction, secretion, receptor capping and nerve growth cone motility (Hartshorne,
1987; Gallagher et al.,1997).
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In vertebrates there are two genes for MLCK (Stull et al., 1986; Gallagher et al., 1997).
One form is expressed in striated muscles and has distinct catalytic and structural
properties that are distinct from the other form. The other form, originally purified from
smooth muscle tissues, was described as smooth muscle MLCK. However, emerging
biochemical and molecular evidence shows that this form is also found in non-muscle
cells (Gallagher et al., 1997). The size of this enzyme ranges from 130 to 150 kDa
depending upon the animal species. Because of its ubiquitous distribution, it is now
commonly referred to as conventional MLCK. Biochemical and molecular research
indicates that MLCK contains a catalytic core that is structurally related to other
serine/threonine protein kinases (Stull et al., 1986; Gallagher et al., 1997). The
regulatory segment involved in autoinhibition and calmodulin binding extends from the
C-terminus of the catalytic core and folds back onto the large lobe of the catalytic core in
the absence of calcium/calmodulin, thereby inhibiting intrasterically RLC binding and
phosphotransferase activity (Kemp & Pearson, 1991; Knighton et al., 1992). The MLCK
contains three immunoglobulin-like and one fibronectin-like motifs and the C-terminal of
the catalytic core/regulatory segments (Olsen & Eckstein, 1990; Gallagher et al., 1991;
Potier et al., 1995). Immunoglobulin-like and fibronectin-like motifs, consisting of about
100 residues, are also found in giant muscle proteins such as titin. The third
immunoglobulin-like motif at the C-terminus has seven strands of an antiparallel βpleated sheet that form a barrel (Holden et al., 1992).

Calmodulin with calcium has a high affinity for MLCK with an averaged Kd or Kcam
value of 1nM (Stull et al., 1986). There are two lobes of calmodulin which can be
separated by limited trypsin cleavage. Biochemical studies of the isolated fragments
show that each is an effectively independent structure capable of activating target
enzymes including MLCK (Newton et al.,1985; Persechini et al.,1994; Persechini et al.,
1996). A mixture of the two lobes results in a greater extent of activation than does either
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lobe alone. Calcium first binds to the high affinity sites in the C-terminal lobe of
calmodulin. As the calcium concentration increases, calcium binds to the two lower
affinity sites in the N-terminal lobe of calmodulin. This results in the subsequent binding
of the second calcium/calmodulin lobe, displacement of the regulatory segment and
exposure of the catalytic cleft for RLC binding. MLCK obviously binds to myosin via a
substrate-enzyme interaction. Biochemical studies show it has a higher affinity for nonphosphorylated myosin (substrate) than for the phosphorylated form (Sellers & Pato,
1984).

Biochemical studies have also shown that MLCK binds to F-actin, but the apparent
binding affinity, with or without tropomyosin, is low relative to what would be expected
from binding to detergent washed myofilaments or skinned fibres (Sellers & Pato, 1984).
At relatively high concentrations in vitro, MLCK bundles F-actin filaments (Hayakawa et
al., 1994) and is able to inhibit the interaction of phosphorylated myosin with F-actin
(Sato et al., 1995). Binding studies to detergent-washed gizzard myofilaments showed
that the full-length MLCK and ∆C-MLCK (deletion of the C-terminal Ig-like motif
alone) bound but the ∆N- (deletion of the N-terminal half-alone) and ∆NC (deletion of
both the N-terminal half and C-terminal IG-like motif) forms did not. MLCK bound with
an apparent higher affinity to detergent-washed myofilaments and to purified smooth
muscle thin filaments than to smooth muscle F-actin or skeletal muscle myofibrils.
Because the apparent binding affinity is greater for purified thin filaments than smooth
muscle F-actin, there may be another protein that facilitates or anchors MLCK to the
actin-containing filaments.

Calcium /Calmodulin -Dependent Protein Kinase II (CaMK II) When calcium binds
to calmodulin to form a calcium/calmodulin complex, the complex will activate a number
of cellular enzymes. One such enzyme is Calcium /Calmodulin -dependent protein kinase
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II (CaMK II). CaMK II is large multimer (~ 600 kDa) protein with 8-10 individual kinase
subunits of about 54-60 kDa each. CaMK II is composed of four subunits (α, β, δ and γ).
The CaMK II present in cultured rat aortic VSM cells is comprised mainly of the δ2subunit variant (Schworer et al., 1993). This kinase undergoes autophosphorylation in
the presence of Calcium/CaM on a specific conserved threonine residue (Thr 286 in the
α-subunit) which results in Calcium/CaM-independent (or “autonomous”) kinase activity
(Hanson et al., 1992). A total of 70-80% of the Calcium/CaM-dependent kinase activity
may become autonomous in vitro under optimal autophosphorylation conditions (Hanson
et al., 1989). Autophosphorylation on Thr286 has also been reported to result in a 1000fold increase in the affinity of the kinase subunits for calmodulin (Meyer et al., 1992).
Inactive CaMK II has a low affinity for calmodulin. The autophosphorylation of CaMK
II is predicted to be a cooperative process requiring at least two activated subunits per
holoenzyme. Intact cells have phosphatase activities that are capable of reversing
autophosphorylation. The possible effect of CaMKII on smooth muscle contraction is by
phosphorylation of myosin light chain kinase. When MLCK is phosphorylated by CaMK
II in vivo, the affinity of MLCK for calmodulin is decreased and the calcium/calmodulin
threshold for activation of MLCK is raised (Stull et al., 1990). In addition, if the CaMKII
specific inhibitor, KN-62, is used in these preparations, the phosphorylation of myosin
light chain by MLCK is potentiated, indicating that there is an inhibitory effect of
CaMKII phosphorylation on MLCK activity (Tansey et al., 1992).

Mitogen-Activated Protein (MAP) Kinase MAP kinases are unique protein kinases
activated in response to many extracellular stimuli. They have been shown to be
involved in multiple functions of cells. The MAP kinase family members may be
classified by two different standards. First, they may be classified according to the
sequence that results in activation when it is phosphorylated. The MAP kinases require
dual phosphorylation of threonine and tyrosine and include TEY, TPY and TGY
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sequences. The second classification scheme is based on the nature of the upstream dual
specificity kinases (MAP kinase kinases) that phosphorylate and activate the MAP
kinases. Regulation of MAP kinase inactivation by specific MAP kinase phosphatases is
stimulus- and cell type-specific.

One TEY member, ERK1/2, is believed to play an important role in mediating
phosphorylation of contractile proteins in the maintenance of sustained smooth muscle
tone. In porcine carotid arteries stimulated by a mechanical load or by vasoactive
agonists, ERK1/2 activity was found to increase by 5- to10-fold (Adam et al., 1995).
Immunofluorescence studies in ferret aorta cells showed that phenylephrine-induced
translocation of cytosolic PKC to the surface membrane was associated with transient
redistribution of ERK1/2 to the surface membrane before cell contraction. Coincident
with cell contraction, ERK1/2 undergoes a second redistribution away from the
plasmalemma and towards contractile filaments. High molecular weight caldesmon (hcaldesmon) has been proposed to be the ERK1/2 substrate. The thin filament proteins
caldesmon and calponin are known to inhibit actomyosin ATPase in vitro and prevent
actin sliding. Inhibition of actomyosin ATPase is relieved by phosphorylation of
caldesmon.

Focal Adhesion Kinase (FAK) Focal adhesion kinase (FAK) is a cytoplasmic tyrosine
kinase with a molecular weight of 120-kDa. FAK is activated by autophosphorylation of
Tyr397 in response to different ligand engagement with integrins (Schlaepfer et al., 1994;
1997). It has been reported that the time course of the increase in FAK tyrosine
phosphorylation in response to contractile stimulation closely follows tension
development in tracheal smooth muscle. The role of FAK in the contractile activation of
tracheal muscle has been studied by utilizing an antisense oligonucleotide to FAK to
selectively deplete FAK protein (Tang et al., 2001). The depletion of FAK protein
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resulted in an inhibitory effect on the development of force, intracellular calcium levels,
and myosin light-chain phosphorylation in response to contractile stimulation with
acetylcholine. After permeabilization with α-toxin and stimulation by increasing
intracellular calcium, the FAK-depleted tissues developed active tension that was
comparable to control tissues. This indicated that the primary cause for the suppression of
contractile activation in the FAK-depleted tissues is possibly the disruption of calcium
signaling. These studies are consistent with electrophysiological studies in vascular
muscle cells that also suggest a critical role for FAK in the regulation of calcium
channels. It has also been suggested that FAK might be part of a complex of proteins that
mediate calcium-insensitive signaling pathways which regulate the contractile apparatus
and cytoskeletal dynamics in smooth muscle (Tang et al., 1999).

Small Heat Shock Protein (HSP27) There are several families of proteins that are
likely to be effectors of actin remodeling, including capping proteins, severing proteins
such as gelsolin (Gusev et al., 1994; Butt et al., 2001;), and cross-linking proteins such as
filamin and α-actinin. Small heat shock proteins might also be important effectors of
actin remodeling or cross-bridge function. HSP27 is a multimer that occurs in various
sizes ranging from dimers to 700-kDa oligimers, with the large (>500 kDa) multimers
predominating. Multimers form from interaction of unphosphorylated dimers.
Phosphorylation of Ser 83 promotes dissociation of multimers (Benndorf et al., 1994),
and further phosphorylation of Ser15 may regulate interaction of dimers with actin
filaments (Lambert et al., 1999). HSP27 has significant effects on actin cytoskeletal
polymerization or depolymerization which are regulated by phosphorylation and
dephosphorylation of HSP27. Purified unphosphorylated mouse and chicken HSP27
homologs inhibit actin polymerization in vitro (Benndorf et al., 1994; Miron et al., 1991)
while phosphorylation reverses the inhibition. This is supported by studies of cultured
cells in which the phosphorylation of HSP27 was shown to be necessary for growth
16

factor stimulating F-actin formation (Lavoie et al., 1993a; and 1993b), the stabilization of
focal adhesions (Schneider et al., 1998), and the promotion of cell migration (Rousseau et
al., 1997). Research of signaling pathways regulating HSP 27 activity in fibroblast and
other nonmuscle cells showed that phosphorylation of HSP27 by MAP kinase-activated
protein (MAPKAP) kinase 2 (MK2) is necessary for formation of F-actin.
Phosphorylation of HSP27 by MK2 increases the rate and extent of actin polymerization
in vitro (Butt et al., 2001). This suggests that, in vivo, the extent of actin polymerization
can be increased by phosphorylation of HSP27 by MK2. MK2 is regulated by p38 MAP
kinases. The p38 MAP kinases are activated by upstream activators MKK3, MKK4 and
MKK6. The pathway between the MKKs and surface receptors is not well defined.
RhoA is also reported to be an upstream activator of HSP27 in smooth muscle. HSP27 is
constitutively expressed in smooth muscles at relatively high concentrations (2-8µg
HSP27/mg total protein) (Miron et al., 1988; Hedges et al., 1999;). HSP27 has been
shown to colocalize with contractile proteins in freshly dispersed intestinal smooth
muscle cells stimulated with ceramide, and has been coprecipitated with actin,
tropomyosin, and caldesmon, suggesting some molecular association with the contractile
elements (Ibitayo et al., 1999). “Stress”stimuli also can activate signal transduction
pathways that induce HSP27 phosphorylation in smooth muscle

The Protein Kinase C (PKC) Family Several hypotheses advanced to explain the
contractile function of smooth muscle based on the results of in vitro research, have
proposed mechanisms involving protein phosphorylation by protein kinase C. PKC was
discovered in 1977 by Nishizuka and co-workers. This discovery represented a major
breakthrough in signal transduction research. PKC has been known as the cellular
receptor for diacylglycerol (DAG), and is therefore a key player in phospholipase C-
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Figure 2.
Schematic representation of structural features of protein kinase C (PKC) isozymes. PKC
polypeptides are depicted as linear chains with an amino terminal regulatory domain and
a carboxyl terminal catalytic domain. Comparison of deduced amino acid sequences
reveals five variable (V1-V5) and four constant (C1-C4) regions. Locations of
pseudosubstrate (PS)-and ATP-binding sites are indicated. Cysteine-rich zinc finger
sequences are located in C1 domains: two in each of cPKC and nPKC isozymes, and one
in the aPKC isozymes. The nPKC and aPKC isozymes lack a C2 domain and exhibit
calcium-independent activity.

coupled signal transduction. PKC is also a high-affinity receptor for the phorbol ester,
which is a tumor promoter involved in multistage carcinogenesis. The activationassociated translocation, the identification of substrate, and the characterization of its
functional role in the cell all form active areas of research.
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The PKC family is a group of serine-threonine kinases implicated in various biological
functions including signal transduction, cell proliferation and differentiation, and smooth
muscle contraction. The PKC family is separated into four subgroups (Fig. 2) based on
their structure and activation requirements (Keenan and Kelleher, 1998; Newton et al.,
1998). The conventional PKC (cPKCs): α, βI, βII, and γ are activated by calcium,
diacylglycerol (DAG) or phorbol ester, and phosphatidylserine (PS). There are additional
activators for cPKC, such as cis-unsaturated fatty acids and lysophosphatidylcholine
(lysoPC). PKC δ, ε, η, and θ are known as novel PKCs (nPKC). Compared with
conventional PKCs, novel PKCs lack a conserved region of homology known as the C2
domain, which allows them to function in a calcium-independent manner. Atypical PKCs
(aPKC), PKC ζ and ι/λ, have only one cysteine-rich zinc finger motif located in their C1
domain compared with the other cPKC and nPKC isozymes, which have two. The aPKCs
do not require DAG or calcium for activation, but are dependent on PS, the only cofactor
required by all three groups. PKCµ (or PKD), a new serine-threonine kinase with
homology to PKC, may form a distinct PKC subgroup (Newton et al., 1998).

Each PKC isozyme is the product of a separate gene with the exception of PKC βI and
βII, which are alternativly spliced variants of the same gene. All of the PKC isozymes are
single chain polypeptides, comprised of an N-terminal regulatory domain (approximately
20-40 kDa) and a C-terminal catalytic domain (approximately 45 kDa). Cloning of the
first isozymes revealed four conserved domains: C1-C4 (Coussens, 1986). The function
of each of these domains has been established by extensive biochemical and mutational
research. The regulatory domain participates in protein-protein interactions that regulate
PKC activity and localization. The catalytic region is the kinase domain and includes
motifs involved in ATP and substrate binding. The regulatory and catalytic domains are
connected by a hinge region that is highly sensitive to proteolytic cleavage by cellular
proteases.
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The C1 domain contains a pseudosubstrate sequence that resembles the sequence around
phosphorylatable serine or threonine residues in the PKC substrate. The pseudosubstrate
sequence may bind to the active site in the catalytic domain and inactivate the PKC.
Conversely, antibodies to the pseudosubstrate sequence completely activate PKC. In the
absence of cofactors, the introduction of a mutation in the pseudosubstrate sequence of
PKCα resulted in a substantial increase in effector-independent kinase activity compared
with normal controls. The C1 domain also contains two cysteine-rich zinc finger
sequences that form the diacylglycerol or phorbol ester binding site. Early experiments
using a [3H] PDBu radioligand revealed that PKC isozymes bind phorbol esters with
high affinity in the presence of phosphatidylserine and that DAG and phorbol esters bind
to the same site. The first implication that cysteine-rich domains act as phorbol ester
binding sites originated from experiments performed in Nishizuka’s laboratory (Ono et
al., 1989), in which either deletion of those motifs in PKCγ or mutation of conserved
cysteines resulted in a loss of phorbol ester binding. Each cysteine-rich domain in PKC
folds into a globular structure. Phorbol esters bind in a groove formed by pulling apart
two β-sheets.

The C2 domain contains the calcium-binging site. PKCs without a C2 domain (novel or
atypical PKCs) or PKCs with a mutation in the C2 domain do not require calcium for
kinase activity or phorbol binding. A great number of proteins containing C2 domains
have been identified to date. Most of them are related to signal transduction mechanisms
or membrane trafficking. Structural analysis has revealed that all C2 domains fold
similarly into a structure consisting of two four-stranded antiparallel β-sheets connected
by variable loops at the end of each strand, with the calcium binding site located at one
end of the domain. The calcium domain acts as a membrane-docking module, where the
calcium ions and basic residues contribute to electrostatic membrane binding. The
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catalytic domain of PKC isozymes includes the C3 and C4 domains. The C3 domain
possesses the binding site for ATP, the C4 domain possesses the binding site for
substrates. It is thought that PKC is maintained in the inactive state by the
pseudosubstrate occupation of this site. Detailed structural information is not available
for the PKC kinase domain; however, it is known that the regulatory catalytic domain is
separated by a hinge region (V3). [Proteolytically generated kinase domain protein kinase
M (PKM)]

Regulation of PKC Activity by Cofactors Experiments using mixed micelles or lipid
bilayers have determined that acidic phospholipids are efficient cofactors for PKC
activation, with PKC having a remarkable selectivity for phosphatidylserine. DAG causes
a dramatic increase in the affinity of cPKCs and nPKCs for phosphatidylserine.
According to the accepted model of PKC activation by lipids, the binding of DAG (or
phorbol esters) in the presence of the phospholipid cofactors induces a conformational
change in PKC that results in the removal of the pseudosubstrate from its binding site and
in the activation of the enzyme. It is believed that the cysteine-rich and C2 domains are
not the only regions involved in phospholipid binding. The pseudosubstrate domain,
once removed from its binding site, may also contribute to membrane binding through its
basic residues. Membrane association is reflected as a shift in the subcellular localization
or ‘translocation’ of cytosolic PKC to membrane compartments in cellular systems, a
process that is also tightly controlled by protein-protein interactions. The association to
membranes and activation of kinase activity are differentially regulated by the cation, and
the concentration of calcium required for membrane binding is substantially lower than
that required for activation. The model postulated by Newton (Keranen and Newton,
1997) suggests that low concentrations of the cation promote weak membrane
interactions, which are accompanied by conformational changes that are insufficient to
promote the activation of the enzyme. Higher calcium concentrations, however, produce
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a conformational change in PKC that results in the release of the pseudosubstrate from its
binding site in the catalytic domain, leading to enzyme activation.

PKC Binding Proteins Research from the past 10 years has made it clear that in
addition to binding to lipids, PKC can also interact with proteins via protein-protein
interactions. It was believed that these interactions play an important role in the
localization and function of PKC isozymes. PKC in an active conformation will bind to
receptors for activated C kinase (RACKs) or substrates that interact with C kinase
(STICKs). Inactive PKCs will interact with a kinase anchoring proteins (AKAPs) and
14-3-3. Hence, PKC binding proteins may or may not be PKC substrates. Such proteins
serve many functions including localizing inactive (AKAPs) or active (RACKs) PKC
isozymes to specific intracellular sites or serving as substrates (STICKs), shuttling
proteins (RACK1), PKC activators, or PKC inhibitors.

RACKs were first characterized as Triton-X-100 insoluble proteins that bind PKC
isozymes only in the presence of PKC activators. Because a PS bridge should not be
sufficient for binding of PKC to these RACKs, it was proposed that the association
involved direct protein-protein interaction. Moreover, PKC binding to RACKs should not
be inhibited by a substrate peptide, indicating that anchorage does not reflect binding of
the catalytic site on PKC to a phosphorylation site on these proteins. The PKC-RACK
interaction is mediated, at least in part, by the C2 region in cPKCs and the C2-like region
(within the V1 region) in nPKCs (Mochly-Rosen et al., 1992; Johnson et al., 1996;
Csukai et al., 1997; Hundle et al., 1997; Yedovitzky et al., 1997; Zhang et al., 1997; Ron
et al., 1999). Two RACKs have now been identified by using overlay assays: RACK1, a
36 KDa protein, which specifically interacts with PKCβII (Ron et al., 1994; 1995) and
RACK2 (β’-COP), which specifically interacts with PKCε. Neither RACK1 nor RACK2
is a PKC substrate, but both increase PKC phosphorylation of substrates (Ron et al.,
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1994; Csukai et al., 1997), suggesting that the PKC-RACK complex may be the active
form of the enzyme in vivo. It was reported that RACK1 exhibits a translocation
response to PKC activation. RACK1 translocates to the same site as activated PKCβII
and specifically associates with this isozyme upon activation. These findings suggest a
potential role for RACK1 as a PKC shuttling protein. A εPKC-selective RACK,
RACK2, has also been identified by expression cloning using a fragment of εPKC that
contains the RACK binding site. It selectively binds εPKC colocalized only with
activated εPKC (and not other isozymes) to cross-striated structures, the perinucleus, and
cell-cell contacts in cardiac myocytes. Prekeris et al. (1996) found that εPKC, and not
other PKC isozymes, binds to filamentous actin (F-actin) in vitro and in synaptosomes.
Because only the activated form of εPKC binds, F-actin appears to have the
characteristics of a εRACK. Blobe and collaborators (1996) have found that, in vivo and
in three different cell lines, F-actin results in stimulation of βIIPKC but not βIPKC.
Binding to F-actin results in the stimulation of βIIPKC which displays altered substrate
specificity when bound to F-actin. These data suggest that F-actin may also have
βIIRACK characteristics. Whether both ε and βIIPKC bind to F-actin in the same cells
and whether their binding is competitive remain to be determined.

STICKs require phosphatidylserine for interaction with PKC and they are PKC
substrates. Phosphorylation of STICKs regulates their association to PKC. STICKs are
involved in a variety of functions. For example, adducin, which is identified as a STICK,
is a cytoskeletal protein involved in the interaction between actin and spectrin (Fowler et
al., 1998). Clone 72, which is another STICK and a major PKC binding protein in REF52
fibroblasts, is involved in cytoskeleton remodeling and cell growth (Chaplin et al., 1996).
Another STICK is the serum deprivation response protein (Sdr) that binds and localizes
PKCα within the microdomain of caveolae (Mineo et al., 1998).
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Scaffolding proteins can enable signaling proteins to cluster. This allows a tight control
of cellular pathways and cross talk between different cascades. Scaffolding proteins
include caveolin (Mineo et al., 1998; Oka et al., 1997), AKAPs (Klauck et al., 1996),
p62/ZIP (Puls et al., 1997), INAD (Xu et al., 1998), and 14-3-3 (Xiao et al., 1995; Meller
et al., 1996). Each of these proteins has the ability to cluster PKC to specific intracellular
sites. PKC scaffolding proteins bind to PKC in its inactive conformation.

Syndecan-4, another PKC interacting protein, is a transmembrane matrix binding
proteoglycan. The cytoplasmic tail of syndecan-4 interacts with the kinase domain of
PKCα, resulting in the localization of PKCα to focal contacts and in the activation of the
isozymes (Oh et al., 1997A; and 1997B). Syndecan-4 can also be phosphorylated in
response to PKC activation (Horowitz et al., 1998). The phosphorylation status of
syndecan-4 does not affect its binding to PKCα, although it regulates its activity
(Horowitz et al., 1998).

Cytoskeletal proteins interact, in part, with PKC in an isozyme-selective pattern.
Examples of this isozyme specificity are PKCζ which associates with tubulin via the
pseudosubstrate region (Garcia-Rocha et al., 1997), and PKCε which specifically binds
F-actin via an actin-binding site within the C1 region (Prekeris et al., 1998). F-actin
activates PKCε in the absence of phospholipids (Prekeris et al., 1998). PKCβII (but not
PKCβI) also interacts with the F-actin cytoskeleton upon activation. PKCβII selectively
phosphorylates actin, although actin is a poor substrate. The interaction of PKCβII with
actin results in a significant increase in autophosphorylation and in an alteration in
substrate specificity. It is thought that the interaction between PKCβII and actin protects
PKC from degradation and down-regulation (Blobe et al., 1996).
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By using an overlay technique and screening of an expression library, Jaken and
collaborators (Hyatt et al., 1994) have identified several additional PKC binding proteins.
These proteins are all substrates of PKC and bind PS directly. A PS bridge between the
binding proteins and PKC has been suggested to mediate this binding. These PKC
binding proteins include talin and vinculin, myristoylated alanine-rich C-kinase substrate,
a β-adducin homolog, AKAP 79, clone 72, and a related gene product, gravin/AKAP250.
The finding that PS alone is sufficient for binding of PKC to these binding proteins
suggests that full activation of PKC is not required. Furthermore, they found that αPKC,
for example, localizes to focal contact structures, where talin and vinculin are found in
nonstimulated fibroblasts and in cultured renal cells. Activation by phorbol esters results
in αPKC translocation away from these proteins, as shown by cell fractionation.

There is a proposed model for PKC binding to its anchoring proteins (Daria and Gorgen,
1998). In this model inactive PKC is depicted as a folded rod with the pseudosubstrate
autoinhibitory sequence at the amino terminus associated with the substrate site in the
catalytic domain (House and Kemp, 1987). Those proteins that anchor inactive C-kinase
are referred to as receptors for inactive C-kinase isozymes, or RICKs. In the presence of
PKC activators, the rod unfolds and the RACK binding site becomes exposed, resulting
in binding of PKC to its RACK. RACK- bound PKC is shown with the substrate binding
site exposed and the RICK binding site unavailable for binding. Although there are no
direct experiments indicating an ability of RICKs and RACKs to associate with PKC,
concomitantly, immunofluoresence data and the inhibition of binding to at least some
putative RICKs in the presence of phorbol ester suggest exclusive binding of the enzyme
either to RICKs or to RACKs (Yao et al., 1997). This scheme also reflects the findings
that although there is a PS bridge between RACK and PKC there is also direct proteinprotein interaction (Mochly-Rosen et al., 1991).
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PKC Expression and Translocation Different cell types express their own unique
complement of PKC isoforms (Dekker and Parker, 1994). Within a cell type, PKC may
be involved in the regulation of a variety of different cell functions. PKC isoforms
identified in vascular smooth muscle (α, β, ε, δ, ζ) (Andrea et al., 1992) are thought to
play key roles in such functions as cell proliferation and differentiation (Montesano and
Orci, 1985) and contractile activity (Rasmussen et al., 1987). The expression of multiple
isoforms regulating diverse functions within a single cell type suggests that individual
isoforms phosphorylate specific substrate(s) and that overlap of PKC isoform activity
may be limited under physiological conditions (Mochly-Rosen 1995; Mochly-Rosen et
al., 1991). This, in turn, would necessitate strict PKC isoform compartmentalization
and/or regulatory control of enzyme activation. The spatial separation of individual
isoforms in the stimulated cell is an important mechanism determining substrate
specificity. Hence, the regulation of PKC activation and its translocation to isoformspecific sites are presently areas of intense research interest.

Prior to stimulation of the cell, the inactive form of PKC is thought to be diffusely
distributed throughout the cytosol or to be localized to specific regions or structures of
the cell. Following cell stimulation, PKC isoforms may translocate from inactive pools
to their active cell loci. Hence, the intracellular translocation of PKC may represent a
major mode of control of isoform function: the targeting of specific isoforms to discrete
cell loci would determine access to substrate. It was originally thought that upon cell
stimulation, conventional, novel and atypical subgroups of PKC isoforms underwent
obligatory translocation to the cell membrane thereby allowing access to lipid co-factors
required for enzyme activation. More recent evidence, however, indicates that PKC
isoforms may translocate to a variety of subcellular structures including membrane
vesicles, perinuclear/nuclear structures, and the cytoskeleton. Colocalization studies have
indicated extensive association of different PKC isoforms with components of the actin
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microfilament (Murti et al., 1992; Allen and Adarem, 1995), microtubules (Lehtich and
Forrest, 1994), and intermediate filaments (Omary et al., 1992; Owen et al., 1996) of the
cytoskeleton in different cell types. Recent interest has focused on the role of PKC as a
regulator of cytoskeletal function. Activation of PKC results in the phosphorylation of an
array of cytoskeletal proteins (Keenan et al., 1998) and is thought to regulate changes in
cytoskeletal structure and organization (Hoshi et al., 1987; Inagaki et al., 1988; Chou et
al., 1990; Murphy et al., 1993).

Several laboratories have reported that the isoform PKCα is translocated from the cytosol
to the plasmalemma in isolated vascular smooth muscle cells (Khalil et al., 1994; Jensen
et al., 1996; Haller et al., 1998) and in intact vascular smooth muscle strips (Haller et al.,
1990). Haller and coworkers (Haller et al., 1996) have shown that PKCα is translocated
from the cytosol to the nucleus in endothelial cells in response to stimulation by a variety
of hormones and growth factors. They have further demonstrated (Haller et al., 1998)
that passaged vascular smooth muscle grown on fibronectin exhibited PKCα
accumulation at both the nucleus and at membrane focal adhesions. Taken together,
these results suggest that the translocation signaling movements of a specific isoform are
not fixed but may vary significantly with the cell type, cell environment, the stimulus
employed, and other factors, possibly including the differentiation state of the cells
studied. Plasticity of PKC translocation signaling between cell compartments would be
expected to greatly expand the potential range of target substrates and cell functions of
individual isoforms.

A7r5 Cell Line The A7r5 cell line is an embryonic smooth muscle cell line with adultlike characteristics (Kimes and Brandt, 1976). The A7r5 clonal cell line was originally
derived from an embryonic rat aorta. A7r5 cells show expression and promoter activity
of several highly restricted smooth muscle markers: smooth muscle α-actin, smooth
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muscle calponin, smooth muscle myosin heavy chain, tropoelastin, and SM 22 alpha
mRNA which is found exclusively in smooth muscle and is considered one of the earliest
makers of differentiated smooth muscle (Firulli et al., 1998). A7r5 cells are characterized
by an inability to proliferate in serum-free medium, the absence of PDGF-B mRNA and
the ability to contract in culture. Thus, it is concluded that A7r5 cells represent a
transcriptionally differentiated smooth muscle. A7r5 cells also showed high transfection
efficiency compared with other smooth muscle cell lines. All these characteristics of
A7r5 cells make it an excellent in vitro model system for smooth muscle research. Their
comparatively slow growth, however, may represent an obstacle for the derivation of
stably transfected cell lines (Firulli et al., 1998).
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II Methods
Cell Culture
A7r5 cells, derived from the embryonic rat aorta and exhibiting an adult smooth muscle
phenotype, were obtained from American Type Culture Collection (Manasass, VA) and
cultured in Dulbeccos modified Eagles medium (DMEM) that was supplemented with
10% fetal bovine serum, 100 units/ml penicillin G, and 100 µg/ml streptomycin.
Cultures were maintained in a humidified atmosphere of 5% CO2 in air at 37°C. The
medium was changed every 2 days and cells were passaged at least once a week by
addition of trypsin/EDTA solution in HBSS.

PKCα-EGFP Plasmid Constructs
A PKCα-EGFP expression plasmid was constructed by inserting PKCα cDNA into
pEGFP-C2 vector (Fig. 3).
PKCα cDNA Digestion: PKCα cDNA in the SRD vector obtained from Dr. Ohno (1987;
Department of Molecular Biology, Yokohama City University School of Medicine,
Yokahama, Japan) was removed using an EcoRI restriction enzyme. To digest PKCα
cDNA, 1.0 µl 10X buffer, 8.5 µl of the PKCα plasmid and 0.5 µl EcoRI were mixed in a
reaction centrifuge tube. EGFP vector was also digested with the EcoRI: 1.0 µl 10X
buffer, 8.5 µl of the EGFP plasmid, and 0.5 µl EcoRI. The two samples were incubated at
37°C for 1 hour for reaction and inactivated at 65°C for 20 minutes. The sample was run
on the gels and appropriate band cut out for purification of the PKCα and for ligation of
EGFP cDNA.
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Figure 3.
Construction of the PKCα-EGFP fusion protein. The full length PKCα cDNA
without the stop codon was inserted into the EcoRI site of the pEGFP-C2 vector
downstream of EGFP. The EGFP was ligated to the V1 domain at the Nterminus of PKCα cDNA.
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PKCα and EGFP Ligation: The PKCα cDNA was ligated into the pEGFP-C2 vector
(Clontech, Palo Alto, CA) downstream of EGFP at the EcoRI site. Five µl PKCα DNA
(~ 150µg) and 3µl EGFP DNA (~ 100µg) were mixed with 1µl 10X buffer and 1µl T4
ligase. This solution was incubated at 16 °C overnight. The sample was then heated at
70 °C for 10 minutes to inactive the ligase reaction. The sample was added to 200µl XL-1
blue competent bacteria (Stratagene: La Jolla, CA) in a microcentrifuge tube, incubated
on ice for 30 minutes, mixed with 800µl LB media (10g/L Bacto peptone, 5g/L yeast
extract, 85.5mM NaCl, pH 7.4) and incubated at 37 °C for 1 hour. The transformed
bacteria (200µl) were spread on agar plates which containing kanamycin (50 µg/ml)
antibiotic, and incubated at 37 °C overnight. Purification of the PKCα-EGFP DNA was
done by Wizard miniprep columns ( Promega, WI) following the manufacturer’s
instructions.
DNA Sequencing: Correct orientation of PKCα-EGFP fusion protein cDNA was
determined by restriction digestion and DNA sequencing. A total of eight samples were
initially tested here by BamH1 restriction enzyme cleavage. Based on the BamH1
cleavage site, the correct constructs were expected to yield two fragments of 2.1Kbp and
5.5Kbp. A possible reversed orientation was expected to produce fragments at 0.8Kbp
and 6.8Kbp. The correct constructs, identified from restriction enzyme digestion, were
further subjected to DNA sequencing to confirm that the inserted DNA was ligated in the
exact reading frame. Nucleotide sequences were determined by the dideoxy chain
termination method (Sanger et al., 1977) using a Sequenase 2.0 sequencing kit
(Amersham; Arlington Hts, IL), following the manufacturer’s instructions. The resulting
plasmid, PKCα-EGFP, contained PKCα fused in frame downstream of EGFP.
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Cell Transfection
Cells were seeded at a density of 4 x 106 cells/100 mm culture dish and transfected with
12 to 18 µg of plasmid using lipofectamine (Life Technologies; Gaithersburg. MD),
according to the manufacturer’s standard protocol. During the course of the project, two
different plasmids were used to transfect A7r5 cells: PKCα-EGFP and a β-actin-EGFP
expression plasmid (Clontech, Palo Alto, CA). First, 12 to 18 µg of plasmid were diluted
in 600 µl serum-free and antibiotic-free DMEM medium (solution A) while 30 µl
lipofectin were diluted in 600 µl serum-free and antibiotic-free DMEM medium (solution
B). Both solutions were incubated at room temperature for 30 minutes, and then
combined and incubated at room temperature for an additional 30 to 45 minutes after
which 4800 µl serum-and antibiotic-free medium were added to the mixed solution.
Cells were rinsed with 6 ml serum-and antibiotic-free medium and then overlaid with the
DNA-lipofectin solution. They were then incubated in a humidified atmosphere of 5%
CO2 in air at 37°C for 10 hours, after which they were returned to complete medium
containing 10% serum. Fluorescence indicating expression of fusion protein, was
typically detected within 2 days. Experiments were performed within 3 or 4 days after
transfection.

Immunostaining of A7r5 Cells
A7r5 cells were fixed and permeabilized by the addition of ice-cold acetone for 1.0
minute. They were then washed with phosphate-buffered saline (PBS) containing 0.5%
TWEEN-20 (PBS-T; pH 7.5) and incubated for 10 minutes in blocking solution (5%
nonfat dry milk in PBS-T). For PKCα staining, the fixed cells were incubated with a
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1:1000 dilution of monoclonal anti-PKCα antibody (UBI, Lake Placid, NY) for 30
minutes at room temperature, washed in PBS-T, and then incubated with Alexa 488labeled anti-mouse secondary antibody (Molecular Probes, Eugene, OR) for 30 minutes.
For PKCα/microtubule or PKCα EGFP/microtubule colocalization experiments, PKCα
was visualized with an Alexa 594-labeled secondary antibody (Molecular Probes,
Eugene, OR). A FITC-labeled anti-β-tubulin primary antibody (Sigma, St. Louis, MO)
was utilized for visualization of microtubules. For α-actin staining, cells were incubated
in a 1:1000 dilution of monoclonal anti-α-smooth muscle actin clone 1A4 FITC-labeled
antibody (Sigma Chemical Co., St. Louis, MO) for 30 minutes at room temperature. For
F-actin staining, the fixed cells were incubated with 2.5µM TRITC-labeled phalloidin
(Sigma Chemical Co., St. Louis, MO) for 30 minutes at room temperature. For alphaactinin and talin staining, the fixed cells were incubated with a 1:1000 dilution of
monoclonal anti-α-actinin (Sigma Chemical Co., St. Louis, MO) and anti-talin antibody
(UBI, Lake Placid, NY) for 30 minutes at room temperature, washed in PBS and then
incubated with Alexa 488-labeled anti-mouse secondary antibody (Molecular Probes,
Eugene, OR) for 30 minutes. Nonspecific binding was determined by incubating cells
with secondary antibody in the absence of primary antibody or by mixing the primary
antibody with an excess of purified PKCα protein prior to incubation with cells.

Confocal Microspcopy
For fixed cells, the coverslips were mounted on a Nikon Diaphot microscope and
confocal microscopy was performed with a BioRad Model 1024 scanning system at 488
nm krypton/argon excitation using a 515 nm long pass barrier filter. This included
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experiments with PKCα-EGFP transfected cells, PKCα, α-actin, talin, and α-actinin
antibody stained cells and phalloidin stained cells. For colocalization studies, confocal
microscopy was performed at 633 nm krypton/argon excitation using a 665 nm red glass
filter with cells immunostained for PKCα or at 488 nm krypton/argon excitation using a
515 nm long pass barrier filter in studies with PKCα-EGFP transfected cells or cells
stained for β-tubulin. Final micrograph images were built by projecting serial Z-plane
image acquisitions and were analyzed using Lasersharp and Confocal Assistant Software
(BioRad, Hercules, CA).
Prior to observation, live A7r5 cells were plated onto 25 mm circle glass coverslips one
day before the experiments. Dynamic change of PKCα-EGFP transfected cells or βactin-EGFP transfected cells was observed by utilizing the BioRad Model 1024 scanning
system at 488 nm krypton/argon excitation using a 515 nm long pass barrier filter.
Each experiment was performed a minimum of three times with at least 30 cells from
fixed preparations and 4 to 6 cells from live preparations evaluated per experiment.
Results were confirmed by at least two observers and phenomenon were judged
significant if observed in 70% or more cells.

Cell Treatments:
A. Concentration-Dependent Phorbol-Induced PKCα Translocation:
Translocation of PKCα was induced by the addition of phorbol 12, 13 dibutyrate (PDBu)
to the incubation medium at final concentrations ranging from 10-5M to 10-9M. Unless
stated otherwise, images were obtained at 10 minutes after cell activation with PDBu.
The microtubular cytoskeleton was disrupted by the addition of colchicine (40 µg/ml)
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and The actin cytoskeleton was disrupted by addition of cytochalasin B (1 µg/ml) to the
medium 20 minutes prior to PDB (10-6M to 10-8M) stimulation.
B. Multi-Agonists-Induced PKCα Translocation:
In studies of live cell preparations, cells were stimulated by phorbol 12, 13 dibutyrate
(PDBu, 10-8 M), thapsigargin (10-5M), A23187 ( 10-5M), angiotensin II (10-6M) or
potassium ( 10-2M) addition to the incubation media. The PKC inhibitor staurosporine
(10-8 M) or a calcium chelator cocktail (EGTA, 10-3M; BAPTA-AM, 10-5M) was added
to the medium 15 minutes prior to additions of contractile agents. Colchicine (40 µg/ml)
and cytochalasin B (1 µg/ml) were added to the medium 20 minutes prior to PDBu
stimulation. In experiments using calcium-free medium, cells were washed (2X) with
calcium-free medium and then incubated in calcium-free medium for an hour before
addition of PDBu and A23187.
C. Actin Remodeling Experiments:
Actin cytoskeletal reorganization was studied in A7r5 cells contracted by additions of 2 x
10-5M A23187 and 2 x 10-6M thapsigargin (Sigma Chemical Co., St. Louis, MO). In
experiments examining the effect of these agents on phorbol ester-induced cytoskeletal
remodeling, cells were activated by additions of 10-8M phorbol 12, 13 dibutyrate (PDBu)
at either 30 minutes before or 20 minutes following the additions of A23187 and
thapsigargin to the medium. In order to determine the effect of calcium-free conditions
on remodeling, cells were washed twice with and then incubated in Ca2+-free DMEM
(Gibco BRL Products, Life Technologies, Rockville, MD) for 1 hour before the addition
of agonists. In a final series of experiments, we examined the effects of 6 different
protein kinase inhibitors (Table 1) on A23187/thapsigargin-induced α-actin
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depolymerization. Each kinase inhibitor was added at 10X its published IC50
concentration 30 minutes prior to the addition of the agonists. Each experiment was
conducted a minimum of three times with the results verified by two observers. Unless
stated otherwise, conclusions were based on the observation that at least 80% of the cells
exhibited the phenomenon.

Table 1. Six different kinase inhibitors were studied in actin remodeling experiments.
Inhibitor

Target Kinase

Staurosporine

General kinase

Bisindolymaleimide I

PKC

H-89

PKA

ML-7

MLCK

KN-93

CaMK II

Genistein

Tyrosine Kinase
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Verification of Effective PKCα-EGFP Transfection
After being washed twice with phosphate-buffered saline solution (PBS), A7r5 cells were
collected at 3 days post-transfection by scraping with a rubber spatula followed by
centrifugation. The harvested cells were suspended in 150 µl of lysis buffer (10 mM
Tris, pH 7.4; 1 mM EDTA, 1 µg/ml leupeptin, 1 µg/ml pepstatin, 50 µg/ml aprotinin, 0.5
mM phenylmethylsulfonyl fluoride (PMSF), and 1% glycerol). Protein concentration
was determined by the BCA (Pierce) protein assay. Equal amounts of protein samples
were electrophoretically separated on 10% SDS-PAGE. The resolved bands were
electrophoretically transferred to a nitrocellulose membrane (Amersham, Piscataway,
NJ). The membrane was incubated with blocking solution (5% nonfat dry milk in PBS)
for 2 hours, repeatedly rinsed with PBS, and then further incubated in a 1:1000 dilution
of either monoclonal anti-PKCα (UBI, Lake Placid, NY) or anti-EGFP (Clontech, Palo
Alto, CA). The blot was washed 3 times in PBS/0.5% Tween and then incubated one
hour incubation with rabbit anti-mouse horseradish peroxidase-conjugated secondary
(Sigma Chemical Co., St. Louis, MO). Reactive bands were visualized by the ELCenhanced chemoluminescence method (Amersham).

Immunoprecipitation of PKCα and EGFP
As an initial step in the kinase activity determinations the PKCα-EGFP and PKCα
proteins were immunoprecipitated for assay. Control A7r5 cells and A7r5 cells
transfected with PKCα-EGFP were harvested from 100 mm culture dishes into 2 ml of
ice-cold lysis buffer [250 mM NaCl, 25 mM Tris-HC1 (pH 7.5), 5 mM EDTA, 1% Triton
100, 2 µg/ml aprotinin, 1 mM phenylmethysulfonyl fluoride (PMSF)] and homogenized
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by repeated pipetting. After centrifugation at 14000 g for 10 minutes, the supernatant
was divided into two aliquots for the addition of anti-PKCα monoclonal antibody or antiEGFP monoclonal antibody. The samples were incubated at 4°C for an additional hour
in a rotary mixer after which protein A was added. The samples were incubated for an
additional hour at 4 °C. The samples were then centrifuged and the pellets were washed
3 times by resuspension in 2 ml of rinse buffer (lysis buffer without Triton 100). The
washed pellet was suspended in 50 µl PBS for the kinase activity assay.

PKCα Activity Assays
PKCα activity was measured using the Pep Tag Assay for non-radioactive detection of
protein kinase C (Promega, Madison, WI) according to the manufacturer’s instructions
(Fig. 4). This assay utilizes a brightly fluorescent peptide substrate that is very specific
for PKC. The amino acid sequence of the PKC-specific substrate, Pep Tag C1 peptide,
is P-L-S-R-T-L-S-V-A-A-K. Phosphorylation of C1 Peptide by PKC changes the
peptide’s net charge from +1 to –1, and this change in the net charge of the substrate
allows the phosphorylated and nonphosphorylated substrate to be separated on an agarose
gel at neutral pH. Phosphorylated substrate moves toward the positive electrode while
the nonphosphorylated substrate migrates toward the negative electrode. Briefly, 10 µl of
sample were mixed with reaction buffer (100 mM HEPES, 6.5 mM CaCl2, 5 mM DTT,
50 mM Mg Cl2, 5 mM ATP, pH 7.4), activator solution (1 mg/ml phosphatidyl serine)
and Pep Tag Cl peptide. The solution was incubated at 30°C for 30 minutes. The
reaction was stopped by placing the sample in a 95°C heating block for 10 minutes. The
samples were electrophoresed on a 0.8% agarose gel at 100V for 20 minutes. The gel
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C1 Peptide substrate
(+1 net charge)
Incubate with PKCcontaining sample

P

Non-phosphorylated
(+1 net charge)

=

Phosphorylated
(-1 net charge)

Separate phosphorylated and non-phosphorylated
C1 by agarose gel electrophoresis

cathode
+1
0

Non-phosphorylated
(+1 net charge)
P

-1
anode

=

Phosphorylated
(-1 net charge)

Figure 4.
Mechanism and procedure of the Pep Tag non-radioactive protein kinase assay. Two µg
of Pep Tag C1 peptide were incubated as described in the standard PKC assay with PKC
sample in a final volume of 25 µl for 30 minutes at room temperature. The reactions
were stopped by incubation at 95°C for 10 minutes, and the samples were
electrophoresed on a 0.8% agarose gel at 100V for 20 minutes. Phosphorylated peptide
migrated toward the anode (+), while nonphosphorylated peptide migrated toward the
cathode (-).
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was photographed under UV light and the signal intensity was quantitated with a
Molecular Dynamic densitometer. The activity of PKCα was normalized for the protein
content of each immunoprecipitation sample and expressed as units/µg protein.

Intracellular Calcium Determination
Loading of Cells with Fura-2:
A7r5 cells were placed in a six well culture plate containing 25 mm diameter glass
coverslips and allowed to grow for 1 to 2 days until they reached 70 to 80% confluency.
The coverslips containing A7r5 cells were removed asceptically from the six well culture
plates, rinsed with HBSS (GIBCO-BRL, NY) and then placed in a Narishige
Microincubation Chamber (Narishige International USA, Inc., NY). The cells were then
incubated in 1 ml HBSS containing 5 µM Fura-2AM (Molecular Probes, Inc., Eugene
OR) and 0.05% w/v Pluronic F-127, a non-ionic detergent that helps to disperse Fura2AM and thus facilitate dye loading into the cells (Molecular Probes, Inc., Eugene, OR)
at 370C for 30 minutes. The cells were then washed three times with HBSS and incubated
in HBSS for 10 min at 370C so as to completely hydrolyse the Fura-2AM. Prior to
imaging the solution was replaced with a 1 ml fresh HBSS.
Digital Video Fluorescence Imaging:
The Narishige microincubation chamber containing Fura-2 loaded A7R5 cells on the
coverslip in HBSS was placed on the stage of a Nikon Diaphot TMD inverted
fluorescence microscope (Nikon Corporation, Tokyo, Japan) maintained at 37°C and
equipped for ratio fluorescence microscopy. The cells were successively excited at
340 nm and 380 nm, and the fluorescence emitted at 510 nm was intensified by a
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DAGE-MTI GenIISys image intensifier (DAGE-MTI, Inc., Michigan City, Indiana)
and finally captured by a DAGE-MTI CCD72 video camera (DAGE-MTI, Inc., Michigan
City, Indiana). The video signals from the CCD72 camera were digitized at 8 bits per
pixel. The fluorescence images were acquired every 15 sec with each set representing an
average of 16 video frames. The ratio images were calculated in real time by pixel to
pixel division of fluorescence images obtained by 340 nm excitation to that by 380 nm
excitation. Metfluor Imaging System, version 4.1.7, software (Universal Imaging
Corporation, Westchester, PA) was used for image acquisition and analysis. The [Ca2+]i
was calculated according to equation of Grynkiewicz et al. (1985) as follows:

[Ca2+]i = KD β (R - Rmin) / (R - Rmax)

where R is ratio of Fura-2 fluorescence emission due to excitation at 340 nm divided by
380 nm excitation, Rmax is the ratio when Fura-2 is saturated with Ca2+ ions (achieved by
using 5 µM ionomycin), Rmin is the ratio when Fura-2 is in the acid form (achieved by
chelating intracellular calcium ions with 20 mM EGTA), β is the ratio of fluorescence of
free Fura-2 in acid form divided by fluorescence of Fura-2 saturated with Ca2+ ions with
380 nm excitation and KD is the dissociation constant for the binding of Fura-2 to Ca2+
ions (a value of 224 nM was used). The in situ calibration of [Ca2+]i was performed at the
end of the experiment by using 5 µM ionomycin followed by 20 mM EGTA. Finally, 50
mM MnCl2 was used to completely quench the fluorescence and thus to obtain
background image emission. All images were corrected for the background emission.
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III Results
Study of Concentration-Dependent Phorbol Induced PKCα Translocation
Characterization of PKCα-EGFP Fusion Protein
In order to determine if the PKCα-EGFP fusion protein was effectively expressed and
retained PKCα enzymatic properties, Western Blot and kinase activity assays were
performed on PKCα-EGFP expressing A7r5 cells. Western Blot analysis indicated PKCα
and PKCα-EGFP exhibited bands at approximately 80 kDa and 110 kDa, respectively
(Fig. 5). Visualization of cells with anti-EGFP antibody yielded a single band at
approximately 30 kD in cells transfected with EGFP vector and a single band at about
110 kD in cells transfected with PKCα-EGFP indicating little or no detectable breakdown
of PKCα-EGFP. Furthermore, significant levels of kinase activity were observed in
samples obtained both by immunoprecipitation of PKCα or EGFP (Fig. 6), indicating that
PKCα-EGFP retained enzymatic activity. Finally, colocalization studies of PKCα and
EGFP indicated identical cellular distribution of endogenous PKCα and PKCα-EGFP
both in control and stimulated cells (Fig. 7).

Translocation of PKCα in Response to Different Concentrations of PDBu
Results from experiments utilizing either standard immunostaining methods (Fig. 8) or
A7r5 cells expressing the PKCα-EGFP fusion protein (Fig. 9) were consistent in
indicating concentration-dependent effects of PDBu on PKCα translocation.
Immunostaining indicated that PKCα was diffusely distributed throughout the cell prior
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to stimulation (Fig. 8A). Addition of PDBu to the medium at final concentrations of 10-5
M and 10-6M resulted in intense immunostaining in the perinuclear/nuclear region with
minor or no fluorescence seen at the cell membrane (Fig. 8 B, C). By comparison, PDBu
at final concentrations of 10-7M and 10-8M caused significant accumulations of PKCα at
the cell membrane with only slight staining noted at the perinucleus (Fig. 8 D, E). PDBu
at 10-9M did not result in PKCα translocation in A7r5 cells (Fig. 8 F). Similar to the
results from immunostaining experiments, A7r5 cells expressing PKCα-EGFP also
showed a diffuse distribution of fluorescence in unstimulated cells although discrete areas
of intense fluorescence at the membrane were often noted in these control cells (Fig. 9).
Addition of 10-6M PDBu resulted in an obvious translocation of the fusion protein to the
perinucleus, whereas 10-8M PDBu caused translocation to the cell membrane (Fig. 9).

Control experiments (data not shown) in which cells were incubated with secondary
antibody in the absence of primary antibody demonstrated that PKCα translocation was
not influenced by nonspecific staining or autofluorescence. In addition, the addition of a
2X molar excess of purified PKCα enzyme with the primary antibody used in the present
experiments resulted in the almost total blockade of immunostaining, further indicating
the specificity of PKCα staining in the A7r5 cell preparation. Finally, it was shown that
the addition of the inactive phorbol ester, 4α-phorbol 12, 13-didecanoate (4α-PDD) had
no detectable effect on PKCα intracellular distribution (Fig.9), indicating that the
translocation phenomenon observed was associated with PKC activation.

Role of the Cytoskeleton in PKCα Translocation in A7r5 Cells
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Figure 10 shows the effect of colchicine treatment on the structure of the microtubule
cytoskeleton of A7r5 cells. The typical A7r5 cell exhibited a pattern of dense central
microtubular structure connected by distinct filaments to an extensive subplasmalemmal
microtubular structure (Fig. 10A). The central microtubular structure and connecting
filaments were disrupted within 10 minutes (Fig. 10 B, C) and the entire microtubular
cytoskeleton was abrogated within 20 minutes after the addition of colchicine to the
medium (Fig.10 D).

Disruption of the microtubules with colchicine had no significant effect on the
distribution of PKCα in unstimulated cells (Figs. 11 A’, 12A’). However, disruption of
the microtubules by a 20 minutes treatment of colchicine consistently resulted in the
blockade of PKCα translocation to the perinuclear region of cells stimulated by the
addition of 10-6M PDB (Figs. 11 B’, 12 B’). By comparison, treatment with colchicine
did not affect the peripheral translocation of PKCα induced by 10-8 M PDB in A7r5 cells
(Figs. 11 C’, 12 C’).

Dual immunostaining for β-tubulin and PKCα indicated little or no direct association of
PKCα with the microtubular system in unstimulated cells (Fig. 13B). Similarly, there
was no evidence of colocalization of PKCα and microtubular structure in A7r5 cells
stimulated by additions of 10-6 M PDB (Fig. 13 D) or 10-8M PDB (Fig. 13 F) to initiate
perinuclear and peripheral translocation, respectively.
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A7r5 cells stained with TRITC-labeled phalloidin showed a system of densely packed
actin stress fibers arranged in parallel and extending across the whole cell body.
Treatment with cytochalasin B caused disruption of actin fibers, primarily at the central
region of the cells (data not shown). Cytochalasin B had no effect on the distribution of
PKCα in unstimulated cells (Fig. 14 A’) and, unlike colchicine, cytochalasin B had no
effect on the translocation response to either 10-6M PDBu (Fig. 14 B’) or 10-8M PDBu
(Fig. 14 C’).

Colocalization of PKCα with p62 and BiP/GRP 78 in Response to 10-6M PDBu
In order to determine whether PKCα was associated with the nuclear envelope or
endoplasmic reticulum in response to 10-6M PDBu stimulation, colocalization studies of
PKCα with nucleoporin p62 and the ER marker BiP/GRP78 were performed. Data
indicated some degree of colocalization of PKCα with p62 and BiP/GRP78 in
unstimulated cells which appears to be increased in 10-6M PDBu stimulated cells (Fig.
15).

45

Figure 5.
Immunoblot analysis of the PKCα-EGFP fusion protein from A7r5 cells. Lane
1, rabbit brain positive control for PKCα; lane 2, control A7r5 cells; lane 3,
A7r5 cells transfected with PKCα-EGFP; lane 4, A7r5 cells transfected with
EGFP; lane 5, A7r5 cells transfected with PKCα-EGFP. Bands detected with
anti-PKCα monoclonal antibody (lanes 1-3) indicated immunoreactivity only
at 80 kDa in control A7r5 cells and at both 80 kDa and 110 kDa in cells
transfected with PKCα-EGFP. Detection by anti-EGFP monoclonal antibody
(lanes 4, 5) indicted immunoreactivity at approximately 29 kDa in cells
transfected with EGFP (lane 4) and only at 110 kDa in cells transfected with
PKCα-EGFP (lane 5) indicating insignificant degradation of the PKCα-EGFP.
The figure shown is a typical of results from three individual experiments.
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Figure 6.
PKCα kinase activity of the PKCα-EGFP fusion protein obtained from A7r5 cells. AntiPKCα and anti-PKCα-EGFP monoclonal antibodies were utilized to immunoprecipitate PKCα
and the PKCα-EGFP, respectively from A7r5 cell samples. PKCα kinase activity was then
measured using the Pep Tag assay method. Precipitated samples were mixed with PKC
activity reaction solution, electrophoresed on a 0.8% agarose gel, and photographed on a
transilluminator under UV light. Phosphorylated peptide can be seen to migrate toward the (+)
(an arrow indicates the phosphorylated peptide), while nonphosphorylated peptide migrates to
the cathode (-). Positive control was purified PKCα protein while negative control contained
distilled water. Results reflect the average of three individual experiments.
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Figure 7.
Confocal micrographs showing dual imaging for PKCα and EGFP in A7r5 cells stimulated
at 10-8 M and 10-6 M concentrations of phorbol 12, 13 dibutyrate (PDB). PKCα was
visualized using an Alexa 594-labeled secondary antibody. Images were collected in
separate channels to prevent overlap of fluorophores. Yellow color in panels at the right of
the figure indicates areas of colocalization of EGFP and PKCα. Because there was no
evidence of significant degradation of PKCα-EGFP, the results indicate that the fusion
protein is translocated in response to cell stimulation in a fashion identical to native PKCα.
Magnification was 600X. The micrographs reflect the results from 3 experiments in which a
total of 88 cells were evaluated.
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Figure 8.
Confocal micrographs showing the concentration-dependent perinuclear and
plasmalemma translocation of PKCα in A7r5 at 10 minutes after exposure to vehicle (A)
or PDBu concentrations of 10-5M (B), 10-6M (C), 10-7M (D), 10-8M (E), and 10-9M (F).
PKCα was visualized by standard immunostaining methods using unlabeled anti-PKCα
primary antibody followed by Alexa 488-labeled anti-mouse IgG secondary antibody.
Magnification was 600X. The micrographs reflect the results from 5 experiments in
which a total of 456 cells were evaluated. It was estimated that at least 90% of cells
exhibited the indicated phenomenon.
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Figure 9.
Confocal micrographs showing the distribution of PKCα-EGFP fusion protein in
unstimulated control A7r5 cells and in cells stimulated by the addition of 10-6M or 10-8M
PDBu. Results are identical to those obtained with standard immunostaining in indicating
that cells stimulated with 10-6M and 10-8M PDBu translocate PKCα primarily to the
perinucleus and plasmalemma, respectively. Inactive phorbol 4αPDD had no effect on
distribution of PKCα. Magnification was 600X. The micrographs reflect the results from 3
experiments in which a total of 212 cells were evaluated. It was estimated that at least 90%
of cells exhibited the indicated phenomenon.
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Figure 10. 1010.10.10.
Normal A7r5 cell microtubular structure (A) and the effects of the microtubule
disrupting drug colchicine on these structures at 5 minutes (B), 10 minutes (C),
and 20 minutes (D) exposures. Microtubules were visualized using a FITClabeled-β-tubulin antibody. Magnification was 600X. The micrographs reflect
the results from 3 experiments in which a total of 410 cells were evaluated.
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Figure 11.
The effect of treatment with colchicine to disrupt microtubules on the distribution of
PKCα in unstimulated and PDBu-stimulated A7r5 cells. Control cells received vehicle
(A) or additions of PDBu at 10-6M (B) or 10-8M (C). Treated cells were exposed to
colchicine (40 µg/ml, 20 min) prior to receiving vehicle (A’), 10-6M PDBu (B’) or 10-8M
PDBu (C’). PKCα was stained with unlabeled anti-PKCα primary antibody (UBI)
followed by Alexa 488-labeled anti-mouse IgG secondary antibody (Molecular Probes).
Magnification was 600X. The micrographs reflect the results from 4 experiments in
which a total of 428 cells were evaluated. It was estimated that an average of 87 ± 6% of
cells exhibited colchicine blockade of perinuclear translocation at 10-6M PDBu.
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Figure 12.
The effect of treatment with colchicine to disrupt microtubules on the distribution of
PKCα -EGFP fusion protein in unstimulated and PDBu-stimulated A7r5 cells. Untreated
cells received vehicle (A) or additions of PDBu at 10-6M (B) or 10-8M (C). Treated cells
were exposed to colchicine (40 µg/ml, 20 min) prior to receiving vehicle (A’), 10-6M
PDBu (B’or 10-8M PDBu (C’). The results were consistent with those from experiments
using standard immunostaining methods in indicating that disruption of microtubules
blocked the perinuclear accumulation of PKCα-EGFP induced by 10-6M PDBu but had no
significant effect on 10-8M PDBu-stimulation of PKCα-EGFP translocation to the
plasmalemma. Magnification was 600X. The micrographs reflect the results from 4
experiments in which a total of 350 cells were evaluated. It was estimated that 86 ± 3% of
cells examined exhibited the loss in perinuclear translocation.
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Figure 13.
Dual immunostaining for β-tubulin and PKC α in unstimulated (A, A’) A7r5 cells and 30s
after the addition of 10-6M PDBu (C, C’) or 10-8M PDBu (E, E’). Microtubules were
stained with FITC-labeled anti-β-tubulin antibody while PKCα was visualized with Alexa
594-labeled secondary antibody. Images were collected in separate channels at laser power
settings below 10% to eliminate bleedover of fluorphores. Rightside panels indicate areas
of overlap in fluorescence (yellow). The micrographs are representative of images
collected in six individual experiments in which a total of 102 cells were evaluated.
Magnification was 600X.
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Figure 14.
The effect of treatment with cytochalasin B to disrupt actin stress fibers on the
distribution of PKCα in unstimulated and PDBu-stimulated A7r5 cells. Control cells
received vehicle (A) or additions of PDBu at 10-6M (B) or 10-8M (C). Treated cells
were exposed to cytochalasin B (1µg/ml, 15 min.) prior to receiving vehicle (A’), 10-6
PDBu (B’) or 10-8M PDBu (C’). PKCα was stained with unlabeled anti-PKCα
primary antibody followed by Alexa 488-labeled anti-mouse IgG secondary antibody.
The original magnification was 600X. Micrographs reflect the results from 3
experiments in which a total of 298 cells were evaluated.
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Figure 15.
Dual immunostaining of PKCα with nucleoporin p62 and PKCα with BiP/GRP78 in
unstimulated A7r5 cells and cells treated with 10-6M PDBu for 15 minutes. PKCα was
visualized by standard immunostaining methods using unlabeled anti-PKCα primary
antibody followed by Alexa 488-labeled anti-mouse IgG secondary antibody (green); p62
and BiP/GRP78 were visualized with Alexa 594-labeled secondary antibody (red). Images
were collected in separate channels to prevent overlap of fluorophores. Yellow color
indicates areas of colocalization of p62 or BiP/GRP78 and PKCα. Magnification was
400X. The micrographs reflect the results from 3 experiments in which a total of 78 cells
were evaluated.
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PKCα Translocation in Response to Different Contractile Agents
Translocation of PKCα-EGFP
Figures 16 through 20 compare the effects of PDBu, A23187, thapsigargin, Ang II and
potassium on PKCα translocation in A7r5 cells expressing PKCα-EGFP. PDBu,
A23187, and thapsigargin were effective contractile agonists, consistently causing
approximately 85% of cells to visibly contract. Ang II and potassium, however, did not
cause detectable constriction of A7r5 cells.

PKCα was diffusely distributed throughout the cell body in unstimulated cells (Figs. 1620). The addition of PDBu to the medium resulted in a slow but robust relocation of
PKCα to the plasma membrane leaving the cytosolic region of the cell devoid of
fluorescence (Fig. 16). Translocation became clearly evident by 8 minutes and was
usually complete within 10 to 20 minutes after addition of PDBu. Thereafter, PKCα
remained localized along the cell periphery for at least 120 minutes.

The calcium ionophore A23187 (Fig. 17) and thapsigargin (Fig. 18) which elevates
intracellular calcium through a blockade of endoplasmic reticulum calcium-ATPase
activity, had similar effects on PKCα translocation. Each caused a robust but transient
translocation of the PKCα to the cell membrane. Relocalization along the cell periphery
was detectable within 1 minute and was completed within 4 minutes after addition of
either agent to the medium. Subsequently, PKCα was observed to slowly redistribute
back into the cytosolic region of the cell over an interval of 10 to 25 minutes.
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By comparison with other agents studied, Ang II caused only a partial translocation of
cellular PKCα which was extremely rapid in development, transient and highly site
specific at the cell periphery. Ang II induced PKCα translocation to discrete areas of the
cell periphery which began to be clearly visible as intensely fluorescing circular patches
as early as 10 seconds after the addition of the drug to the medium (Fig. 19). This
translocation response was further distinguished by the rapidly transient nature of PKCα
localization at these sites. The depletion of PKCα from peripheral patches was often
observed within 1 minute, with the distribution of the enzyme returning to that of the
unstimulated cell by 5 minutes after Ang II addition.

Both the spatial and temporal patterns of the potassium-induced PKCα-EGFP
translocation were different from the other agents studied. About 10 minutes after
potassium stimulation, PKCα was observed to move slowly from the cytosol to the cell
membrane, a process which continued to completion over an interval of approximately 20
minutes. At completion, most of the PKCα was localized at the cell membrane.
However, detectable amounts were observed as granular structure scattered throughtout
the cell body (Fig. 20).

Blockade of PKCα Translocation
A combination of calcium chelators has been previously demonstrated to block PKCγ
translocation in response to A23187 but not to the phorbol ester 12-0-tetradecanoyl
phorbol 13-acetate in COS-7 cells (Sakai et al., 1997). In order to determine if PKCα
translocation exhibited similar calcium requirements in A7r5 smooth muscle cells, the
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effects of a mixture of EGTA (2 X 10-3M) and BAPTA-AM (10-5M) were examined in
A23187- and PDBu-stimulated cells (Fig. 21). Addition of calcium chelators to the
medium completely blocked both PKCα translocation and the contraction of A23187treated cells. Similarly, calcium chelators blocked the translocation of PKCα in response
to PDBu and caused a partial inhibition of contraction (Fig. 21).

Staurosporine at high concentrations is an inhibitor of a broad spectrum of protein
kinases, but was expected to be selective for PKC activity at the concentration (10-8M)
employed in the present experiments. Staurosporine had no effect on PKCα translocation
but blocked the contraction of PDBu-stimulated cells (Fig. 22). Staurosporine had no
effect on either PKCα translocation nor the contraction of cells treated with A23187.

Disruption of the microtubules by colchicine (40 µg/ml) had no effect on 10-8M PDBuinduced PKCα translocation to the cell membrane or cell contraction. By comparison,
disruption of actin filaments by treatment of cytochalasin B (1 µg/ml) showed no effect
on 10-8M PDBu-induced PKCα translocation to cell membrane, however it partly blocked
the 10-8M PDBu-induced cell contraction (Fig.23). Neither colchicine nor cytochalasin B
had a detectable effect on A23187-induced PKCα translocation to the cell membrane or
cell contraction (data not shown).

Incubation of cells in calcium-free medium blocked PDBu-induced PKCα translocation
to the cell membrane and attenuated cell contraction compared to PDBu-treated cells in
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regular medium (Fig. 24). Both PKCα translocation and cell contraction in response to
A23187 were blocked in calcium-free medium (Fig.24).
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Figure 16.
Confocal micrographs showing the spatial and temporal translocation of PKCα-EGFP in a
A7r5 cell stimulated with 10-8M phorbol, 12, 13 dibutyrate (PDBu). Relocalization of the
fusion protein from its diffuse distribution in the cytosol was complete within 10 to 20
minutes and was irreversible in the presence of PDBu. Results are representative of those
obtained in 5 individual experiments in which total of 70 cells were evaluated. The original
magnification was 400X. The bar indicates 50 microns.
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Figure 17.
Confocal micrographs showing the spatial and temporal translocation of PKCα-EGFP in a
A7r5 cell stimulated by 2 x 10-5M A23187. Relocalization of the fusion protein from its
diffuse distribution in the cytosol to the plasma membrane was completed within 1 to 4
minutes. Subsequently, the protein was seen to redistribute slowly into the cytosol over a
20 to 25 minute interval. Results are representative of those obtained in 5 individual
experiments in which a total of 58 cells were evaluated. The original magnification was
400X. The bar indicates 50 microns.
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Figure 18.
Confocal images showing the spatial and temporal translocation of PKCα-EGFP in a
A7r5 cell stimulated with 10-5M thapsigargin. Thapsigargin stimulated PKCα-EGFP
translocation from the cytosol to the plasma membrane within 0.5 to 1.0 minutes.
Translocation was completed within 4 minutes. Subsequently, the protein was
observed to slowly redistribute from the membrane to the cytosol over an interval of 5
to 10 minutes. At 60 min, the readministration of thapsigargin induced a second rapid,
but not reversible, PKCα-EGFP translocation to the plasma membrane without further
cell size change. Results are representative of those obtained in 3 individual
experiments in which a total of 56 cells were evaluated. The original magnification
was 400X. The bar indicates 50 microns.
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Figure 19.
Confocal micrographs showing the spatial and temporal translocation of PKCα-EGFP
in A7r5 cells after addition of 10-6M angiotensin II to the media. Translocation of the
fusion protein was observed as early as 10 seconds after addition of the drug and was
highly localized at brightly fluorescing patches at the cell periphery. Subsequently, the
protein was observed to redistribute from the membrane to the cytosol over an interval
of approximate 2 minutes. Note that no evidence of cell contraction was obtained in
studies of angiotensin II. Results are representative of those obtained in 3 individual
experiments in which a total of 30 cells was evaluated. The original magnification was
400X. The bar indicates 50 microns.
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Figure 20.
Confocal images showing the spatial and temporal translocation of PKCαEGFP in A7r5 cell stimulated with 10-2 M potassium. (A) Control, (B)
relocalization of the PKCα was started within 10 minutes, (C) 20 minutes
after potassium stimulation and (D) completed within 30 minutes.
Translocation of PKCα was irreversible in the presence of potassium and
most of PKCα-EGFP flourescence accumulated at the cell membrane.
However, detectable amounts were observed as granular structures scattered
throughtout the cell body. Results are representative of those obtained in 4
individual experiments in which a total of 50 cells were evaluated. The
original magnification was 400X. The bar indicates 50 microns.
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Figure 21.
Effect of the combination of 2 x 10-3M EDTA and 10-5M BAPTA-AM calcium chelators
on the translocation of PKCα-EGFP in A7r5 cells stimulated with (A) A23187 or (B)
PDBu. Calcium chelators blocked the translocation of the fusion protein in response to
both agents. Micrographs are representative of results obtained in 3 individual
experiments in which 30 cells were evaluated. The original magnification was 400X.
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Figure 22.
Effect of the serine/threonine PKC activity inhibitor, staurosporine, on the translocation of
PKCα-EGFP in A7r5 cells stimulated by additions of A) 10-5M PDBu and B) 2 x 10-5M
A23187. Staurosporine had no effect on the translocation of the fusion protein in either
treatment but blocked the contractile response to PDBu. Micrographs are representative
of results obtained in 3 individual experiments in which a total of 35 cells were evaluated.
The original magnification was 400X.
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Figure 23.
Effect of cytochalasin B and colchicine on PKCα-EGFP translocation. Disruption of
actin filaments with cytochalasin B did not affect A23187 or PDB-induced PKCα-EGFP
translocation. It was also shown that disruption of microtubules with colchicine had no
effect on PKCα-EGFP translocation from the cytosol to the plasma membrane.
Micrographs are representative of results obtained in 3 experiments in which a total of 40
cells were evaluated. The original magnification was 400X. The bar indicates 50
microns.
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Figure 24.
Effect of PDBu and A23187 on PKCα-EGFP distribution and cells size change in a
calcium-free medium. In the calcium-free medium, PDBu and A23187 failed to
stimulate a significant translocation of PKCα-EGFP. PDBu stimulation induced a
reduction of cell size while A23187 stimulation did not. Results are representative of
those obtained in 3 individual experiments in which a total of 60 cells were evaluated.
The original magnification was 400X. The bar indicates 50 microns.
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Calcium-Dependent Actin Remodeling in Contracting A7r5 Cells
A7r5 Cell Contraction.
The effects of A23187 and thapsigargin were effectively identical on the contraction and
dynamics of the actin cytoskeleton, suggesting that the mechanism of increased [Ca2+]i
had little or no effect on A7r5 smooth muscle contraction. Both agents caused a
sustained increase in [Ca2+]i which plateaued or continued to increase throughout the
interval of observation. Figure 25 shows the results from a typical experiment examining
the effect of A23187 and thapsigargin on [Ca2+]i. The change in [Ca2+]i of 11 individual
cells in response to thapsigargin is summarized in Table 2. Basal [Ca2+]i ranged between
60nM and 120nM ( X = 81.4 ± 6.4 nM). The addition of thapsigargin (5 x 10-6M) caused
a biphasic response, with an initial slow phase of increase lasting about 10 minutes
followed by a secondary increase in [Ca2+]i. The maximum increase in [Ca2+]i ranged
from 220 to 611 nM ( X = 507.2 ± 40.7 nM), which typically occurred at about 17
minutes after the addition of thapsigargin. After an early phase of [Ca2+]i increase,
periodic oscillations of varying frequency and amplitude were clearly observed. Such
oscillations are a common feature of the increase in [Ca2+]i in stimulated cells of various
types (Thaler et al., 1992). Administration of 2 x 10-5M 4-Bromo-A23187 induced an
immediate increase of [Ca2+]i which reached a plateau at 852 ± 21 nM. The calcium
concentration then fell to baseline level over the next 4 to 6 minutes. After declining to
the baseline level, the intracellular calcium did not respond to the addition of ionomyocin
(Fig. 25), suggesting a possible leakage or inactivation of the Fura-2 dye. A further study
of the uptake of Ca45 in ionophore-treated cells indicated that the intracellular calcium
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levels were elevated by 2 to 6 times for at least 30 minutes after addition of 2 x 10-5M
A23187 (Table 3).
Stimulation through the elevation of [Ca2+]i (A23187/thapsigargin) or the use of phorbol
ester (PDBu) resulted in different patterns of A7r5 cell contraction. The contractile
response to A23187 and thapsigargin was more rapid in onset, shorter in duration, and
less robust than that obtained with PDBu (Fig. 26). Cell constriction in response to
PDBu could be first observed at about 10 to 14 minutes and continued over an interval of
60 to 120 minutes. In the great majority of cells, contraction to PDBu was extremely
strong, such that the resolution of individual actin fibers was lost within 40 to 45 minutes.
By comparison, the responses to A23187 and thapsigargin elevations in [Ca2+]i were
observed as early as 2 to 6 minutes and were completed by 20 to 30 minutes. However,
the response was well maintained with little or no evidence of change in cell dimensions
after completion of constriction. Cell contraction by these agonists exhibited thread-like
extrusions and detached cell remnants on the glass substrate, indicating the forcible
detachment from peripheral adhesion sites. Disruption of actin filaments by treatment
with cytochalasin B (1 µg/ml) caused the precontracted cells to lose the ability to contract
further and there was a visible elongation in the cell x-axis (Fig. 27).

Actin Remodeling
Figure 28 shows the changes in β-actin stress cables during cell shortening in an A7r5
cell expressing β-actin-GFP. The β-actin cables shortened without evidence of
compression throughout the interval of contraction. Because individual fibers could be
identified throughout the interval of contraction, the results further indicate that
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shortening was achieved without β-actin cable disassembly and reassembly of new
structures. Staining of A23187-and thapsigargin-treated cells with phalloidin confirmed
the presence of an extensive system of actin stress cables in contracted cells (Fig. 29);
however, these experiments showed a degree of diffuse staining suggesting some loss in
F-actin. Because diffuse staining was not noted in unstimulated cells (Fig. 29) nor was
diffuse fluorescence observed in stimulated cells expressing β-actin-GFP (Fig. 28), the
results suggest that the increase in [Ca2+]i was associated with loss in α-actin structure.
Immunostaining of control A7r5 cells showed that α-actin was incorporated into thick
stress cables similar in appearance to β-actin cables. Addition of A23187 or thapsigargin
to elevate [Ca2+]i resulted in partial to complete dissolution of α-actin cables (Figs. 30).
The dissolution of α-actin fibers started approximately 2 minutes after stimulation and
was completed by approximately 15 minutes. Figure 31 shows enlarged images of both
A23187- and thapsigargin-stimulated cells, indicating the partial to complete loss in αactin fiber structure following elevation of [Ca2+]i.

Previous work has demonstrated that the crosslinking protein, α-actinin, is colocalized
with α-actin in the A7r5 cell, both in the resting cell and during PDBu-induced α-actin
remodeling (Fultz et al., 2000). Similar to these findings, α-actinin was observed to form
filamentous strands in unstimulated cells (Fig. 32 A, D). The addition of A23187 or
thapsigargin to elevate [Ca2+]i resulted in the dispersal of the protein which was
completed after 15 minutes of stimulation (Fig. 32 C, F), further indicating a general
dissolution of α-actin. By comparison, the treatment did not significantly alter the
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cellular distribution of talin (Fig. 33), suggesting that the effect was confined to the
destabilization of α-actin cable structure.

Effect of Increased [Ca2+]i on PDBu-Induced α-Actin Remodeling
PDBu caused remodeling of α-actin into brightly fluorescing peripheral bodies with a
reduction in the numbers of α-actin fibers (Fig. 34B). The addition of A23187 (Fig. 34D)
or thapsigargin (Fig. 34F) 30 minutes prior to the addition of PDBu resulted in the
depolymerization of α-actin cables and blocked PDBu-induced remodeling. In corollary
experiments, it was further shown that the addition of A23187 or thapsigargin to cells
pretreated with PDBu also caused dissolution of remodeled α-actin peripheral bodies’
structure (Fig. 35).

Effect of Ca2+-Free Medium on Actin Remodeling
A7r5 cells incubated in calcium-free DMEM media for 1 hour did not contract in
response to PDBu, A23187, or thapsigargin. Incubation in the calcium-free medium had
no detectable effect on the integrity of β-actin cables in unstimulated cells or in the
presence of the three agonists (Fig. 36 B, D, E, H and G). After changing back to regular
media, PDBu, A23187, or thapsigargin did not show a detectable effect on β-actin cable
structure (Fig. 36 C, F, I). By comparison, the calcium-free medium blocked α-actin
disassembly by A23187 and thapsigargin and prevented PDBu-induced remodeling (Fig.
37 B, D, E, H, G). Similar to β-actin, no effect on the integrity of α-actin cables was
noted in unstimulated cells incubated in calcium-free medium. Cells returned to the
calcium containing medium and examined immediately failed to show formation of
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peripheral dense structure in response to PDBu or dissolution of α-actin cables in
response to A23187 or thapsigargin (Fig. 37 C, F, I). Incubation in regular medium for 2
hours after the calcium-free medium, however, restored the effect of PDBu on formation
of peripheral dense structure formation and the effects of A23187 or thapsigargin on
dissolution of α-actin (data not shown).

Effect of Kinase Inhibitors on Depolymerization of α-Actin Structure
The effects of six different kinase inhibitors on calcium-induced α-actin cable dissolution
were evaluated (Table 4). Staurosporine (ser/thre inhibitor), bisindolymaleimide (PKC
inhibitor), H-89 (PKA inhibitor), KN-93 (CAMK II inhibitor), and genistein (tyrosine
kinase inhibitor) had no detectable effect on A23187-or thapsigargin-induced α-actin
cable disassembly. Only ML-7, a selective inhibitor of myosin light chain kinase
(MLCK), caused a partial inhibition of this phenomenon (Fig. 38E, F).

82

1000

700

600
5 µM Ionomycin

500

2+

5 µM Ionomycin

[Ca ]i, nM (Thapsigargin)

800

[Ca2+]i, nM (4-Br A23187)

900

4-Bromo A23187
BASELINE
THAPSIGARGIN

400
300

200

100

0

-100
-5

0

5

10
Time (min)

15

20

25

Figure 25.
The time course of increase in [Ca2+]i in A7r5 smooth muscle cells after the addition of 5
x 10-6M thapsigargin or 2 x 10-5M 4-Bromo-A23187. Cells were loaded with Fura-2AM
approximately fifty minutes prior to imaging with a Nikon Diaphot TMD inverted
fluorescence microscope. Tracings show the averaged results from eleven different
control (baseline) and treated cells. Ionomycin was added at the termination of the
experiment for calibration purposes and to demonstrate continued cell responsiveness.
Cells were successively excited at 340nm and 380nm light and the fluorescence emitted at
510nm was captured on a DAGE-MTI video camera. [Ca2+]i was then calculated by the
equation of Grynkiewicz et al. (1985).
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Table 2. Thapsigargin increased [Ca++]i
The basal [Ca++]i in individual A7r5 cells was determined in HBSS by using a ratio
fluorescence microscopy procedure with Fura-2 as a fluorescent probe (see Materials and
Methods). The magnitude of a 5 µM thapsigargin-induced increase in the [Ca++]i in
individual cells was calculated 17 minutes after the addition of thapsigargin.
[Ca++]i, nM

Cell
Number
In HBSS

1
2
3
4
5
6
7
8
9
10
11

68
94
71
58
68
109
91
93
51
118
75

Increase in [Ca++]i, nM

In 5 µM thapsigargin
380
578
434
498
659
588
702
604
271
511
354
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312
484
363
440
591
479
611
511
220
393
279

45
Table 3.
Ca-uptake by A7r5 cells at selected time intervals after addition of the
ionophore A23187. Results reflect the averages from five or six individual cell cultures.

5 min

10 min

30 min

Control

237 ± 15

193 ± 90

393 ± 120

A23187

653 ± 120*

1324 ± 102*+

846 ± 109*

Data are presented as dpm/cell culture well. An (*) or (+) indicates significant difference from control and 5 minute
value, respectively, p < 0.05.
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Figure 26.
The contractile response of A7r5 smooth muscle cells to 10-8M phorbol 12, 13 dibutyrate
(PDBu); the calcium ionophore, A23187 (2 x 10-5 M ); and 2 x 10-6M thapsigargin. Cells were
transfected with β-actin-GFP expression plasmid to enable visualization of single cell
shortening. Cells are shown prior to stimulation (control) and at 30 and 60 minutes after the
addition of agonists. Micrographs represent the results from 16 separate experiments in which a
total of 76, 62, and 56 cells were examined in response to PDBu, A23187, and thapsigargin,
respectively. The original magnification was 400X. The scale bar indicates 50 microns.
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Figure 27.
The effect of cytochalasin-induced dissolution of the actin on cell length in the
precontracted A7r5 cell. Cells were contracted by 10-8 M PDBu 30 minutes prior to
the addition of 0.1 µg/ml cytochalasin B to the media for up to 40 minutes. A7r5 cell
was transfected with an β-actin-GFP expression plasmid. The results show that
within 10 minutes the cell began to elongate in the x-axis (arrow) parallel to the
visible β-actin stress cables. Micrographs are representative of images collected in 3
separate experiments in which 8 cells were evaluated. The original magnification
was 600X.
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Figure 28.
The shortening of individual β-actin stress fibers during an A23187-induced
contraction. A7r5 cells were transfected with β-actin-GFP expression plasmid 3 days
prior to experimentation. Micrographs show the cell A) prior to stimulation and B)
10 minutes, C) 30 minutes, and D) 60 minutes after the addition of A23187. Arrows
indicate two individual fibers that can be identified throughout the interval of
contraction. The original magnification was 400X. The scale bar indicates 50
microns.
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Figure 29.
Confocal micrographs showing the effects of A23187 and thapsigargin on cellular F-actin.
A7r5 cells were stained with TRITC-labeled phalloidin prior to stimulation (A, B), 20 minutes
after A23187(C, D), and 20 minutes after thapsigargin (E, F). Micrographs represent the results
from 3 separate experiments in which a total of 106 unstimulated, 95 A23187-treated, and 96
thapsigargin-treated cells were evaluated. The original magnification was 400X. The scale bar
indicates 50 microns.
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Figure 30.
Confocal micrographs of α-actin structure in unstimulated A7r5 cells (Control; A, D);
cells treated with A23187 for 2 minutes (B) and 15 minutes (C); and cells treated with
thapsigargin for 2 minutes (E) and 15 minutes (F). Cells were stained with
monoclonal anti-α-smooth muscle actin clone 1A4FITC-labeled antibody.
Micrographs represent the results of 4 separate experiments in which a total of 126
control, 198 A23187-treated, and 182 thapsigargin-treated cells were evaluated. An
average of 76 ±3% of treated cells showed significant loss of α-actin fibers. The
original magnification was 400X. The scale bar indicates 50 microns.
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Figure 31.
High magnification imaging (2500X) of α-actin structure at 15 minutes after
treatment with A23187 (C) and thapsigargin (D). Boxes indicate the portion of
cell selected for visualization (A, B). Cells were stained with monoclonal anti-αsmooth muscle actin clone 1A4 FITC-labeled antibody. Images are
representative of those obtained in 3 separate experiments indicating that
treatment with either compound to elevate [Ca2+]i resulted in partial to complete
depolymerization of the α-actin cytoskeletal structure.
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Figure 32.
Confocal micrographs showing the distribution of α-actinin in unstimulated control
cells (A, D), cells stimulated with A23187 for 2 minutes (B) and 15 minutes (C), and
cells stimulated with thapsigargin for 2 minutes (E) and 15 minutes (F). A7r5 cells
were stained with anti-α-actinin primary antibody followed by Alexa 488-labeled
secondary antibody. Micrographs represent the results from 3 separate experiments in
which a total of 102 control, 110 A23187-treated, and 106 thapsigargin-treated cells
were evaluated. An average of 80 ± 3% of treated cells showed dispersal of α-actinin.
The original magnification was 400X. The scale bar indicates 50 microns.
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Figure 33.
Confocal images showing the distribution of talin in unstimulated control cells and in cells
treated with A23187 for 2 minutes and 15 minutes. A7r5 cells were stained with anti-talin
primary antibody followed by an Alexa 488-labeled secondary antibody. Micrographs
represent the results of 3 separate experiments in which a total of 120 control and 130
A23187-treated cells were evaluated. An average of 95 ± 3% of treated cells were judged
to be indistinguishable from control cells. The original magnification was 400X. The
scale bar indicates 50 microns.
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Figure 34.
A comparison of the effects of A23187 and thapsigargin on α-actin cytoskeletal structure in
previously unstimulated cells (-PDBu) and cells in which PDBu was added to induce α-actin
remodeling 20 minutes after the addition of A23187 and thapsigargin (+PDBu). Control
panels show α-actin structure in unstimulated cells (A) and after PDBu alone (B). Other cells
were incubated for 20 minutes with A23187 (C) or thapsigargin (E) or were successively
these drugs for twenty minutes followed by an additional 30 minutes exposure to PDBu (D,
F). Cells were stained with monoclonal anti-α-smooth muscle actin clone 1A4 FITC-labeled
antibody. Images represent the results from 3 separate experiments in which a total of 205
A23187 + PDBu and 215 thapsigargin + PDBu cells were evaluated. The original
magnification was 400X. The scale bar indicates 50 microns.
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Figure 35.
The effect of A23187 and thapsigargin on α-actin cytoskeletal structure in A7r5 cells
precontracted with 10-8M PDBu. Cells were exposed to PDBu for 15 minutes to initiate
remodeling and the A23187 or thapsigargin was added for an additional 15 minutes. α-Actin
was visualized using a monoclonal anti-α-smooth muscle actin clone 1A4 FITC-labeled
antibody. Micrographs represent results from 3 separate experiments in which an average 90
± 3% of treated cells showed dissolution of α-actin structure. The original magnification was
400X. The scale bar indicates 50 microns.
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Figure 36.
A study of the effect of PDBu, A23187 and thapsigargin on the distribution of B-actin
stress fibers in calcium-free media. A7r5 cells were transfected with a β-actin-EGFP
expression plasmid. PDBu treated cells (B), A23187 treated cells (D) and thapsigargin
treated cells (G) show no loss of β-actin fibers. PDBu treated cells, PDBu + A23187
treated cells (E) and PDBu + thapsigargin treated cells (H) show no loss of β-actin
fibers. The addition of calcium back to media did not cause any change of PDBu
treated cells (C), PDBu + A23187 treated cells (F) or PDBu +thapsigargin treated cells
(I). Micrographs represent the results from 3 separate experiments in which a total of
388 cells were evaluated. The original magnification was 400X. The scale bar
indicates 50 microns.
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Figure 37.
A study of the effect of PDB, A23187 and thapsigargin on the distribution of α-actin
stress fibers in calcium-free media. A7r5 cells were stained with a monoclonal anti-αsmooth muscle actin clone 1A4 FITC-labeled antibody. Control cells (A), A23187 treated
cells (D) and thapsigargin treated cells (G) show no loss of α-actin fibers in calcium-free
media. PDBu treated cells(B), PDBu + A23187 treated cells (E) and PDBu + thapsigargin
treated cells (H) also have intact actin fiber structures. The addition of calcium back to
media did not cause any change in PDB treated cells (C), PDBu + A23187 treated cells
(F) or PDBu + thapsigargin treated cells (I). Micrographs represent the results from 5
separate experiments in which a total of 448 cells were evaluated. The original
magnification was 400X. The scale bar indicates 50 microns.
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Figure 38.
The effect of myosin light chain kinase inhibitor, ML-7 on A23187 and thapsigarginmediated dissolution of α-actin structure. Cells were visualized by staining with
monoclonal anti-α-smooth muscle actin clone 1A4 FITC-labeled antibody. The
dissolution of α-actin cables (B, C) was partially blocked by ML-7. Micrographs
represent results from 3 separate experiments in which a total of 204 ML-7-treated cells
were evaluated. The original magnification was 400X. The scale bar indicates 50
microns.
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Table 4.
The effect of different kinase inhibitors on A23187-induced dissolution of
α-actin structure.
Target Kinase

Concentration

α-actin dissolution

Ser/Thr

7 x 10-10M

- -

Bisindolymaleimide I

PKC

1 x 10-8M

- -

H-89

PKA

3.7 x 10-6M

- -

ML-7

MLCK

5 x 10-7M

+ -

KN-93

CAMK II

3 x 10-7M

- -

Inhibitor
Staurosporine

Genistein

-6

Tyrosine Kinase

2.5 x 10 M

- -

A negative (-) or positive (+) indicates no effect or an inhibitory effect, respectively, of the inhibitor against A23187-

induced α-actin depolymerization.
Target kinase: general serine/threonine kinase inhibitor (ser/thr); protein kinase C(PKC); protein kinase A(PKA);
myosin light chain kinase (MLCK); calmodulin kinase II (CAMK II).
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IV Discussion

PKCα translocation
It is now thought that the various PKC isozymes differ in substrate specificity and
sensitivity to activators. This conclusion is consistent with the observation of multiple
isozymes within different cell types which indicate isozyme-specific functions despite
apparently minor differences in amino acid composition (Chalfant et al., 1996). It is
further thought that the high degree of PKC isoform specificity achieved in the cell is due
to the localization of each isoform at specific subcellular sites. The translocation and
compartmentalization of PKC isoforms in stimulated cells is thought to be of importance
in enzyme activation and access to target substrates. Our experiments indicate that
PKCα-EGFP fusion protein retained the enzymatic characteristics of PKCα and was a
suitable probe for the study of translocation in A7r5 cells. Western blot analysis
indicated that the fusion protein was effectively expressed and showed little or no
evidence of degradation (Fig. 5). PKCα-EGFP retained kinase activity (Fig. 6) and
showed a pattern of distribution identical to endogenous PKCα in unstimulated and
PDBu-activated cells (Fig. 7). Translocation of PKCα-EGFP fusion protein was calcium
dependent (Fig. 24). Moreover, the inactive phorbol ester 4α-PDD did not cause
translocation, further suggesting that the cellular relocation of the fusion protein was due
to the activation of PKC. These results are consistent with the findings of Sakai et al.
(1997) who studied the translocation of PKCγ-GFP fusion protein in three different cell
lines. They observed that the addition of GFP had no effect on distribution within the
cell and concluded that the fusion protein provided a useful tool for the investigation of
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the molecular mechanisms of PKCγ translocation. Others have successfully used the
expression of different GFP fusion proteins to study cytoskeletal dynamics in several
mammalian cell lines (Atten et al., 1998), further indicating the general utility of this type
of probe.

In recent work, Wang et al. (1999) have demonstrated a phorbol 12-myristate 13-acetate
(PMA) concentration-dependent translocation of PKCδ-GFP fusion protein in Chinese
hamster ovary cells. The present findings extend their observation, indicating a similar
phorbol ester concentration-dependent translocation of PKCα to the plasmalemma or
nucleus of A7r5 smooth muscle cells. The results suggest that the mechanism for
translocation of a specific PKC isoform to different primary target sites in response to
variation in stimulus strength may occur in widely differing cell types. The potentially
obligatory role of microtubules in phorbol ester-induced perinuclear translocation of
PKCα raises the possibility of unexpected complexity of PKC isoform regulatory activity
in different cells.

PKC activation is tightly linked to translocation. Therefore, translocation movements of
individual PKC isoforms have been investigated in different cell types under a variety of
stimulus conditions. The available evidence indicates that the target site of an individual
PKC isoform can vary among even closely related cell types. For example, PKCα has
been shown to translocate to the perinucleus of cultured cells derived from canine
pulmonary artery (Damron et al., 1998) and rat aorta (Haller et al., 1998) but is
translocated to the plasmalemma in freshly isolated ferret portal vein smooth muscle
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(Khalil et al., 1996). It has been reported that PKCα is translocated to cytoskeletal
structures in angiotensin II-stimulated cells derived from the adult rat aorta (Haller et al.,
1998) and to both the cell nucleus and cell membrane focal adhesions when these cells
are grown on fibronectin (Haller et al., 1998). Overall, research suggests that the
translocation target site of an individual PKC isoform may be different among cell types
and altered by different stimuli.

PKCs, which serve an important signal transduction function, interact with different
components of the cytoskeleton and may play a central role in the regulation of
cytoskeletal dynamics, while contributing to a variety of cytoskeletal-mediated cell
functions. PKC isoforms have been shown to be extensively associated with cytoskeletal
components and are thought to phosphorylate a large number of cytoskeletal-associated
proteins (Atten et al., 1998; Meininger et al., 1999; Nakhost et al., 1998). It was
demonstrated that PKCα associates with cytoskeletal filaments in angiotensin IIstimulated, but not PDGF-stimulated, vascular smooth muscle cells (Haller et al., 1998),
suggesting that the association of this PKC isoform is specific to the stimulus utilized.
Other research showed that PKC plays a key role in cell proliferation and differentiation
(Montesano et al., 1985; Wang et al., 1997a; 1997b) as well as the contractile function of
smooth muscle (Rasmussen et al., 1987; Wang et al., 1997B). Inhibition of PKC
prevents cell spreading in nonmuscle (Vuori and Ruoslahti, 1993) and smooth muscle
cells (Haller et al., 1998), suggesting a role in the formation (Clark and Brugge, 1995;
Lewis et al., 1996; Walters et al., 1996) or disruption (Jaken et al., 1989) of cell focal
adhesions. The role of PKC in smooth muscle contraction is not clearly understood. It
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has been proposed that it is involved in several steps in the force generating mechanism
ranging from increasing calcium influx through activation of voltage gated calcium
channels to the phosphorylation of myosin light chain, myosin light chain kinase, myosin
light chain phosphatase and several other proteins thought to regulate the interaction
between myosin and actin filaments (Akiyama et al., 1986; Horowitz et al., 1996; Kebe
and Hartshorne, 1985; Masuo et al., 1994; Sobue and Sellers, 1991). In light of the
extensive literature linking PKC to cytoskeletal function and the activities of
cytoskeletal-associated proteins, the inhibition of PKC translocation by disruption of the
microtubules may reflect a cytoskeletal protein/PKCα interaction enabling movement to
or docking at perinuclear sites. Alternatively, the results could be indicating an event
mediated downstream of PKC activation that involves cytoskeletal components required,
either directly or indirectly, for PKCα docking at the perinucleus. Because there was no
clear evidence of colocalization of PKCα with microtubules during the interval of
translocation (Fig. 13), suggesting that the mechanism does not require direct association
of PKCα with microtubules, we consider an event downstream or parallel to PKCα
activation a more likely explanation of the present results in A7r5 cells. The lack of an
effect of cytochalasin B disruption of actin stress fibers on PKCα localization at either the
cell membrane or perinucleus of PDBu-stimulated cells (Fig. 14) further indicates that the
association between the cytoskeleton and PKCα translocation is highly specific to the
microtubules.

It is interesting to note that perinuclear localization was observed at PDBu concentrations
well above those necessary to fully activate PKC. One possibility is that high levels of
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the phorbol ester resulted in the activation of other proteins affecting PKCα translocation.
In addition to activation of the conventional and novel isoforms of PKC, substantial
evidence now exists for phorbol ester-induced biological effects mediated via PKCindependent pathways (Rapuano and Bockman, 1997). At least 3 families of proteins
have been identified as phorbol ester receptors (Kazanietz, 2000). The ras guanylreleasing protein (ras-GRP) has been proposed to play a role in cell growth and malignant
transformation through PKC-independent regulation of ras activity. The chimaerins are a
family of proteins for which the α1 isoform has been demonstrated to exhibit GTPaseactivating protein (GAP)-like activity for the GTP binding protein Rac, a central
regulatory molecule in many cytoskeletal-related cell functions. Furthermore, the α2and β2- chimaerins possess an N-terminal SH2 domain that may enable binding to
phosphotyrosine proteins, suggesting that the chimaerins could be involved in more than
one signaling pathway. Other potential phorbol ester receptors (Unc-13, Ca1DAGGEF1) have been shown to bind phorbol esters with high affinity but are less well studied
with regard to their biological properties. Hence, a number of phorbol ester-responsive
proteins have been described which act through GTP-binding proteins to influence a
variety of cell functions. To our knowledge, however, these or similar proteins have not
been described in smooth muscle.

Within the cytosol, interactions of PKC with actin filaments, microtubules and
intermediate filaments have been reported (Jaken and Jones, 1992). There are several
other reports indicating a role of the cytoskeleton in the translocation response of PKCα.
Schmaltz et al. (1996) showed that the transport of PKCα from the cytosol into the
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nucleus of NIH 3T3 cells was blocked by disruption of either the microtubules or actin
cytoskeleton without affecting the nuclear import of a karyophilic reporter protein
containing a canonical nuclear localization sequence (NLS). Battistella-Patterson et al.
(2000), however, found that colchicine disruption of microtubules but not cytochalasin
disruption of actin microfilaments, blocked PDBu-induced perinuclear localization of
PKCα in passaged smooth muscle cells. Their observations coupled with present
findings suggest that the effects of colchicine are highly selective for perinuclear
translocation and do not represent the nonspecific effect of a generalized loss in
cytoskeletal integrity. It is observed that disruption of one kind of filament affects the
integrity of others. Disruption of microtubules leads to a collapse of intermediate
filaments into a ring around the nucleus (Murti et al., 1992). It is possible that PKCα
perinucleus translocation is, in part, related to other cytoskeleton components.

Studies from several laboratories have established that the specific isoform PKCα is
translocated from the cytosol in stimulated vascular smooth muscle cells. However, there
has been considerable disagreement over the target site, suggesting that the spatial pattern
of PKCα cellular movements may differ under the influence of a variety of factors.
Plasticity in the signaling movements of an individual isoform could greatly expand its
range of target substrates and could explain the multiple functional properties attributed
to individual PKC isoforms by different laboratories. To investigate the potential for
variable localization of PKCα at subcellular sites, we directly observed translocation in
live cells expressing PKCα-EGFP. Studies were conducted in a single cell type under
consistent cell culture conditions.
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Our results confirm earlier reports that A7r5 cells retain responsiveness to vasoactive
compounds (Byron et al., 1996) and may contract by both calcium-dependent and
calcium-independent mechanisms (Nakajima et al., 1993). The absence of contractile
response to Ang II (Fig. 19) further suggests that, while these cells exhibit clear
responsiveness to the elevation of intracellular calcium concentration (thapsigargin,
A23187) and activation of PKC (PDBu), they lacked the capability for receptor-mediated
contraction to this compound.

The results indicate that the spatial and temporal relocalization of an individual PKC
isoform (α) markedly differed depending on the stimulating agent. The direct activation
of PKC with 10-8M PDBu caused an irreversible relocalization of PKCα to the
plasmalemma which required 10 to 20 minutes for completion (Fig. 16). Agents
employed to elevate intracellular calcium concentration (A23187, Fig. 17; thapsigargin,
Fig. 18) caused a rapidly transient translocation to the plasmalemma. In this case the
relocalization of PKCα at the cell membrane was completed within 4 minutes with a
slower redistribution back into the cytosol in the subsequent 25 minutes. By comparison,
angiotensin II caused an extremely rapid transient location of PKCα to intensely
fluorescing membrane patches (Fig. 19). In this case the translocation of PKCα to
membrane sites was completed within seconds and return of the fusion protein to the
cytosol within 1 or 2 minutes. Potassium stimulation induced a slow translocation of
most of PKCα to the cell membrane, while small amounts were also observed as granular
structures scattered throughout cytosol (Fig. 20). Because these experiments were
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conducted under identical conditions, the results indicate a remarkable range in the
temporal and spatial translocation movements of an individual PKC isozyme within a
single cell type.

Our finding of concentration-dependent and agonist-dependent variations in PKCα
translocation raises questions regarding the mechanisms which regulate PKC movements
and/or docking at specific subcellular sites. We consider two possibilities likely: (1) an
ATP-requiring transport process that involves active PKC protein translocation via a
mechanism involving a microtubular component of the cytoskeleton; (2) simple diffusion
may provide the driving force, while the targeting mechanisms center on the regulation of
the availability of high-affinity binding sites at different subcellular location. To our
knowledge, the possibility of active PKC translocation has not been investigated.

There are a number of potential mechanisms affecting PKC localization at specific
subcellular sites. (1) Binding of calcium or diacylglycerol to PKC in the presence of
phosphatidylserine causes a conformational change in the molecule that results in the
exposure of the pseudosubstrate domain (Orr et al., 1992; Bosca and Moran, 1993) and
increases hydrophobicity of the molecule, which, in turn, facilitates binding of the PKC
to membrane lipids. (2) Phosphorylation of PKC would significantly affect the affinity of
the protein for the lipid environment. Phosphorylation of PKC has been reported to be
required for it to act as an effector-dependent kinase (Cazaubon and Parker, 1993). The
phosphorylation sites of PKC have been identified as located in the catalytic domain in
both α-PKC (Cazaubon and Parker, 1994) and β-PKC (Zhang et al., 1994). (3) It has

111

been suggested that PKC contains activator independent binding sites for arginine-rich
polypeptides distal to the catalytic site (Leventhal and Bertics, 1993). These binding sites
may allosterically activate PKC, but they may also allow targeting of PKC to specific
subcellular locations. (4) Specific receptors for PKC, such as RACKS, allow the
targeting of PKC to different subcellular sites.

Taken together, the evidence clearly suggests that the signaling movements of PKCα may
be significantly different depending on cell type or differentiation state (BatistallaPatterson et al., 2000, Li et al., 2001), cell environment (Haller et al., 1998), stimulus
intensity (Li et al., 2001), and stimulating agonist (present results). The localization of an
individual isoform at different subcellular sites may most likely be explained by concepts
of specific protein binding of PKC. However, mechanisms that acutely regulate the
availability of protein binding at substrate target sites have not been proposed or are
poorly defined. The magnitude of difference in the time requirement for visible
translocation and completion of relocalization at specific sites in response to different
agonists further suggests that the rate of PKC isoform activation or activation of binding
sites may play a role in PKCα translocation. The concept of simple diffusion of PKC
isoforms to available binding sites may not adequately explain the complex directional
signaling movements observed.

Summary
The results of present studies indicate that the A7r5 cell type has the capability to acutely
alter the translocation of an individual PKC isoform (PKCα) to a different subcellular
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target site, depending upon the concentration of stimulating agent (PDBu) or the agonist
employed. The translocation of PKCα to the perinucleus but not the plasma membrane is
dependent on an intact microtubular cytoskeleton. Because PKCα perinuclear
translocation does not involve direct association of PKCα with microtubules, it is
unlikely that the cytoskeleton is directly involved in the directed movement of the PKCα
isoform. This further suggests the role of the cytoskeleton may center on events
downstream or parallel to PKC activation that enable PKCα movement to and/or docking
at a specific location. The spatial and temporal characteristics of PKCα translocation
were markedly different in A7r5 cells stimulated with different contractile agents. The
results may explain how individual isoforms can exert multiple functional effects through
the selective phosphorylation of different substrates via translocation to different
locations in a single cell type. Mechanisms which regulate the selective PKC binding to
different subcellular sites are not known.

Actin remodeling in the Contracting A7r5 Cell
It is well accepted that the temporal and spatial regulation of intracellular calcium
concentration is crucial in the regulation of contractility in smooth muscle (Somlyo,
1985). However, repeated observations of dissociation between [Ca2+]i and force
development have led to the concept of modulated calcium sensitivity of the smooth
muscle contractile protein. Fay et al. (1979) provided the first simultaneous
measurements of [Ca2+]i and tension in single smooth muscle cells, demonstrating a
transient increase in light emission in aequorin-injected cells from toad stomach muscle
which decreased to near pre-stimulus levels before the onset of mechanical events.
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Morgan and Morgan (1982 and 1984) subsequently showed that receptor-mediated
contraction of vascular smooth muscle evoked a transient elevation of [Ca2+]i with peak
concentration reached at activation followed by a decline to near basal levels at the
completion of force development and the subsequent plateau and maintenance of tension.
This pattern of calcium transient and dissociation of [Ca2+]i and force has been confirmed
by numerous laboratories using different techniques in a variety of smooth muscle cell
types (Ishii et al., 1989; Ozaki et al., 1989; Rembold and Murphy, 1986; Himpens and
Casteels, 1987; Himpens et al., 1988; Cross et al., 2000). Remarkably, one class of
contractile agonist, phorbol esters, has been reported to cause contraction of smooth
muscle without an elevation of [Ca2+]i (Sybertz et al., 1986; Itoh and Lederis, 1987; Jiang
and Morgan, 1987). Others, however, have noted increased [Ca2+]i in phorbol esterinduced contractions (Rembold and Murphy, 1988; Nakajima et al., 1993; Kaneda et al.,
1995; Murthy et al., 2000), suggesting these agonists do have at least a low level calcium
requirement which could differ among cell types. In the present studies with A7r5 cells,
A23187 and thapsigargin caused a sustained or increasing elevation of [Ca2+]i during the
interval of observed cell contraction. This suggests to us that the conditions of increased
[Ca2+]i were not physiological but may more closely reflect events initiated at high Ca2+
concentration normally occurring during the early phase of force development following
cell activation.

The present work extends previous findings of different modes of α-and β-actin
remodeling to contractions elicited by increased [Ca2+]i. Both A23187 and thapsigargin
caused visible constriction of cells in which β-actin cables were observed to shorten
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without evidence of disassembly (Fig. 28). By comparison, the elevation of [Ca2+]i
resulted in the destabilization and loss of α-actin structure in the majority of cells by the
completion of cell contraction (Figs. 30, 31). Dissolution of actin filaments in the
presence of high calcium concentration has been previously observed (Miyauchi et al.,
1994) and may be explained by the activation of known microfilament severing proteins
such as gelsolin (Ebisawa et al., 1985; Kwiatkowski, 1999). However, the concomitant
dispersal of the α-actin-associated crosslinking protein, α-actinin (Fig. 32), the absence of
change in the cellular distribution of talin (Fig. 33), and the lack of an effect on the
integrity of the system of β-actin stress cables (Fig. 28) suggest that the destabilizing
effect of increased [Ca2+]i was highly specific to α-actin cable structure.

The present results support the contention of Fultz et al. (2000) that the separation into
distinct domains (Small et al., 1986) as well as the different modes of α- and β-actin
remodeling, reflect different functions of the two isoforms during contraction. The
shortened duration of the contractile response with concomitant, selective loss of α-actin
cytoskeletal structure in A23187-and thapsigargin-treated cells is consistent with a direct
involvement of α-actin in force development. Similarly, the maintenance of the cell in
the contracted configuration at the cessation of cell shortening and after the
depolymerization of α-actin, concomitant with normal β-actin cable shortening and
stability, is consistent with a role of β-actin cable in tension maintenance.

We consider it probable that the degree of α-actin depolymerization seen in present
studies represents an exaggerated response due to the sustained high levels of [Ca2+]i
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induced by the agonists employed. This conclusion is supported by the further
observation that PDBu-mediated α-actin remodeling was also blocked by high [Ca2+]i.
Finally, incubation of cells in a calcium-free medium indicated that the loss of α-actin
structure was indeed due to the elevation in [Ca2+]i. Interestingly, these latter
experiments also indicated that the calcium-free medium inhibited PDBu-induced α-actin
remodeling, suggesting that this activity has a requirement for at least low [Ca2+]i levels.
Taken together, these results suggest that the pattern of transient increase in [Ca2+]i
induced by physiological agonists could be important in the sequential activation of
different Ca2+ concentration-dependent contractile activities. In addition to activating
myosin ATPase activity and rapid force development, the initial high levels of [Ca2+]i of
the calcium transient could also serve to initiate α-actin destabilization preparatory to
remodeling and a slower mode of force development. Alternatively, the peak in [Ca2+]i
could serve to inhibit α-actin remodeling during the initial phase of force development.
The inhibition of high [Ca2+]i -induced α-actin depolymerization by ML-7 suggests that
myosin light chain kinase (MLCK) could act as part of a pathway regulating the stability
of α-actin cytoskeletal structure. However, we emphasize the need for caution in the
interpretation of results from these experiments. Although studied at 10X, its IC50
concentration, ML-7 was, at most, only partially effective in preventing the loss in αactin cable structure (Fig. 38). Moreover, the general serine/threonine kinase inhibitor,
staurosporine, which was expected to inhibit MLCK at the concentration used, had no
effect on α-actin dissolution by increased [Ca2+]i. In light of these observations, the
protective effect of ML-7 on α-actin structure was likely not due to a direct effect of the
inhibition of MLCK on α-actin dynamics. Studies of calcium-dependent stress relaxation
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of smooth muscle have suggested that the relaxant response to stretch involves
remodeling of the actin cytoskeleton triggered by the strain placed on the tension bearing
elements of the system (Wright and Battistella-Patterson, 1998). By way of speculation,
initial force development due to spiking of [Ca2+]i in the activated cell could provide an
obligatory perturbation in the distribution of strain on actin cables for triggering
remodeling activity. Hence, an action of ML-7 to reduce or inhibit initial force
development could indirectly influence actin remodeling.

Summary
The present results confirm earlier observations of different modes of remodeling of αactin and β-actin isoforms in the contracting A7r5 cell and extend these findings to
include contractions induced through the elevation of [Ca2+]i. Our findings are consistent
with separate primary functional roles, namly, the direct involvement of α-actin in force
development and the remodeling of β-actin to maintain tension. Based on present
findings, we speculate that the calcium transient reported in receptor-mediated activation
of smooth muscle cells is of physiological importance in regulating the appropriate
sequence of primary contractile events. In addition to activating maximal myosin
ATPase activity and early force development, the peak in [Ca2+]i may trigger
destabilization of α-actin cable structure, enabling active remodeling as [Ca2+]i declines.

Based on the present results and other recent findings (Fultz et al., 2000), we propose a
modification of an earlier proposed mechanism of smooth muscle contraction by
Battistella-Patterson et al. (1997). Figure 39A depicts a theoretical system indicating that
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α-actin and β-actin are segregated into separate cytoskeletal domains. Immediately
following agonist stimulation and elevation in [Ca2+]i, the cell complement of αactin/myosin contractile protein contracts, resulting in relatively rapid early force
development and perturbation in the distribution of mechanical strain in the system (Fig.
39B). This, in turn, initiates a cycle of β-actin stress cable shortening to preserve gains in
tension (Fig. 39C) and α-actin remodeling to modulate mechanical advantage of the
contractile protein (Figs. 39 D, E, F). In preloaded tissues or cells, the attainment of
equilibrium between force generating capacity and opposing load would result in the
plateau of active tension and restoration of balance in mechanical strain within the system
(Fig. 39G). The plateau in tension would be characterized by very low level remodeling
and contractile protein activity with the establishment of a stable tension bearing system
(Wright and Hurn, 1994). The model predicts (1) an unexpectedly high level of force
generating capacity due to modulation of mechanical advantage at the contractile protein;
(2) slow force development during combined remodeling and contractile protein activity;
(3) virtually unfettered shortening in length of unloaded cells and; 4) low energy tension
maintenance cost.
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Figure 39.
Proposed model explaining force development and maintenance of active tension in
smooth muscle. Resting mode with inactive contractile protein and associated β-actin
stress bearing cables (A). Agonist stimulation of increased [Ca2+]i, activation of early
force development, and alteration in the distribution of strain (B). Activation of β-actin
remodeling (C) serving to preserve gains in tension during α-actin disassembly (D). αActin reassembly (E) serving to optimize actin/myosin overlap for additional contractile
activity at shortened length (F). Plateau in active force development with cessation of
remodeling and establishment of a stable system of tension bearing elements (G).
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